<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001935.pub2" GROUP_ID="ENT" ID="274799071911441632" MERGED_FROM="" MODIFIED="2011-04-04 12:20:33 +0200" MODIFIED_BY="Jenny Bellorini" REVIEW_NO="0027" REVMAN_SUB_VERSION="5.1.0" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.2">
<COVER_SHEET MODIFIED="2011-04-04 12:20:33 +0200" MODIFIED_BY="Jenny Bellorini">
<TITLE MODIFIED="2010-10-21 09:58:34 +0100" MODIFIED_BY="[Empty name]">Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children</TITLE>
<CONTACT MODIFIED="2011-04-04 12:20:33 +0200" MODIFIED_BY="Jenny Bellorini"><PERSON ID="13477" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Ruth</FIRST_NAME><LAST_NAME>Lewis</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>lewisr17@Cardiff.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care and Public Health</DEPARTMENT><ORGANISATION>Cardiff University</ORGANISATION><ADDRESS_1>Centre for Health Sciences / North Wales Clinical School</ADDRESS_1><ADDRESS_2>School of Medicine, Gwenfro Building</ADDRESS_2><CITY>Wrexham</CITY><ZIP>LL13 7YP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)1978 727340</PHONE_1><FAX_1>+44 (0)1978 261258</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-04-04 12:20:33 +0200" MODIFIED_BY="Jenny Bellorini"><PERSON ID="53FDA3B182E26AA200991D56EB4F5315" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sharon</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Simpson</LAST_NAME><POSITION>Senior Research Fellow</POSITION><EMAIL_1>simpsonsa@cf.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care and Public Health</DEPARTMENT><ORGANISATION>School of Medicine, Cardiff University</ORGANISATION><ADDRESS_1>Heath Park</ADDRESS_1><CITY>Cardiff</CITY><ZIP>CF14 4XN</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 0 2920 687168</PHONE_1></ADDRESS></PERSON><PERSON ID="13477" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Ruth</FIRST_NAME><LAST_NAME>Lewis</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>lewisr17@Cardiff.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care and Public Health</DEPARTMENT><ORGANISATION>Cardiff University</ORGANISATION><ADDRESS_1>Centre for Health Sciences / North Wales Clinical School</ADDRESS_1><ADDRESS_2>School of Medicine, Gwenfro Building</ADDRESS_2><CITY>Wrexham</CITY><ZIP>LL13 7YP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)1978 727340</PHONE_1><FAX_1>+44 (0)1978 261258</FAX_1></ADDRESS></PERSON><PERSON ID="11947" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Judith</FIRST_NAME><LAST_NAME>van der Voort</LAST_NAME><POSITION>Consultant Paediatrician</POSITION><EMAIL_1>vander-voortjh@cf.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Nephrology</DEPARTMENT><ORGANISATION>University Hospital of Wales</ORGANISATION><ADDRESS_1>Division of Paediatrics</ADDRESS_1><ADDRESS_2>Heath Park</ADDRESS_2><CITY>Cardiff</CITY><ZIP>CF4 4XN</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="13387" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Christopher</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Butler</LAST_NAME><POSITION>Professor of Primary Care Medicine</POSITION><EMAIL_1>butlercc@cf.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care and Public Health</DEPARTMENT><ORGANISATION>School of Medicine, Cardiff University</ORGANISATION><ADDRESS_1>Heath Park</ADDRESS_1><CITY>Cardiff</CITY><ZIP>CF14 4XN</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 0 2920 687168</PHONE_1><FAX_1>+44 0 2920 540129</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-12-01 09:23:41 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="26" MONTH="8" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="8" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="8" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2011-03-28 13:21:12 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-03-28 13:21:12 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>We included one new study (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) and excluded three further studies (<LINK REF="STD-Ortega-del-Alamo-2005" TYPE="STUDY">Ortega del Alamo 2005</LINK>; <LINK REF="STD-Cengel-2006" TYPE="STUDY">Cengel 2006</LINK>; <LINK REF="STD-Choung-2008" TYPE="STUDY">Choung 2008</LINK>).</P>
<P>The conclusions regarding the use of oral steroid at short-term follow up remain the same, but the evidence for the effectiveness of oral steroid plus antibiotic therapy is stronger than that of the use of oral steroid alone. There is also imperfect evidence suggesting that the use of oral steroid plus antibiotic may be effective at intermediate follow up. We no longer conclude that there is evidence of short-term improvement with topical intranasal steroid with or without antibiotics. The conclusions regarding long-term outcomes remain the same.</P>
<P>We have adopted the Cochrane 'Risk of bias' tool for assessment of study quality (which involved reassessing the studies included in the previous version of the review). We have also incorporated 'Summary of findings' tables, used the I² statistic to assess heterogeneity and changed the analysis method for dichotomous outcomes from odds ratio (OR) using a fixed-effect method to risk ratio (RR) using a random-effects method.</P>
<P>The authorship of the review has also changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-11-30 13:35:47 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>We ran new full searches in August 2010.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-03-28 13:21:33 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-03-28 13:21:33 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>Correction to analyses headings and labels following feedback (unpublished).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-23 14:14:20 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-11-23 10:15:42 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-11-30 12:42:21 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="8" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-11-18 12:10:59 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-11-18 12:00:21 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-11-18 11:59:54 +0000" MODIFIED_BY="[Empty name]">
<NAME>Department of Primary Care and Public Health, Cardiff University</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Supports the salaries of Butler, Simpson and Lewis.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2010-11-18 12:00:21 +0000" MODIFIED_BY="[Empty name]">
<NAME>Wales School of Primary Care Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Chris Butler has administrative support provided by the School.</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-11-18 12:10:59 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-11-18 12:10:59 +0000" MODIFIED_BY="[Empty name]">
<NAME>NHS Wales Office for Research and Development for Health and Social</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>now called The National Institute For Social Care and Health Research All-Wales (NISCHR)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-04-04 11:15:59 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-03-29 12:05:25 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Oral or topical nasal steroids for hearing loss associated with otitis media with effusion (glue ear) in children</TITLE>
<SUMMARY_BODY MODIFIED="2011-03-29 12:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>Glue ear (otitis media with effusion - OME) is sticky fluid in the middle ear that does not cause pain or fever but can reduce hearing. Steroid drugs (taken orally or as nose spray) are sometimes used to try to speed up the resolution of effusion and so prevent hearing loss. Other treatment options include oral antibiotics and other medicines, or surgical procedures such as grommets (ventilation tubes). This review of trials found that oral steroids (especially when used in combination with antibiotics) speeded up the resolution of OME in the short term. However, there was no long-term evidence to show lasting benefit or improved hearing. There was no evidence that using steroid drugs as a nose spray benefited children with OME.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-03-28 13:21:58 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Otitis media with effusion (OME) is common and may cause hearing loss with associated developmental delay. Treatment remains controversial. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-01-26 15:52:41 +0000" MODIFIED_BY="[Empty name]">
<P>To examine the evidence for treating children with hearing loss associated with OME with systemic or topical intranasal steroids.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-03-28 13:21:58 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane ENT Group Trials Register; CENTRAL; PubMed; EMBASE; CINAHL; Web of Science; BIOSIS Previews; Cambridge Scientific Abstracts; mRCT and additional sources for published and unpublished trials. The date of the most recent search was 26 August 2010.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-11-23 10:31:05 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials of oral and topical intranasal steroids, either alone or in combination with another agent such as an oral antibiotic. We excluded publications in abstract form only; uncontrolled, non-randomised or retrospective studies; and studies reporting outcomes by ears (rather than children).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-02-23 10:07:38 +0000" MODIFIED_BY="[Empty name]">
<P>The authors independently extracted data from the published reports using standardised data extraction forms and methods. We assessed the quality of the included studies using the Cochrane 'Risk of bias' tool. We expressed dichotomous results as a risk ratio (RR) and continuous data as weighted mean difference (WMD), both with 95% confidence intervals (CI). Where feasible we pooled studies using a random-effects model and performed tests for heterogeneity between studies. In trials with a cross-over design, we did not use post cross-over treatment data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-03-28 11:08:44 +0100" MODIFIED_BY="[Empty name]">
<P>We included 12 medium to high-quality studies with a total of 945 participants. No study documented hearing loss associated with OME prior to randomisation. The follow-up period was generally limited, with only one study of intranasal steroid reporting outcome data beyond six months. There was no evidence of benefit from steroid treatment (oral or topical) in terms of hearing loss associated with OME. Pooled data using a fixed-effect model for OME resolution at short-term follow up (&lt; 1 month) showed a significant effect of oral steroids compared to control (RR 4.48; 95% CI 1.52 to 13.23; Chi² 2.75, df = 2, P = 0.25; I² = 27%). Oral steroids plus antibiotic also resulted in an improvement in OME resolution compared to placebo plus antibiotic at less than one month follow up, using a random-effects model (RR 1.99; 95% CI 1.14 to 3.49; five trials, 409 children). However, there was significant heterogeneity between studies (P &lt; 0.01, I² = 69%). There was no evidence of beneficial effect on OME resolution at greater than one month follow up with oral steroids (used alone or with antibiotics) or intranasal steroids (used alone or with antibiotics) at any follow-up period. There was also no evidence of benefit from steroid treatment (oral or topical) in terms of symptoms.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>While oral steroids, especially when used in combination with an oral antibiotic, lead to a quicker resolution of OME in the short term, there is no evidence of longer-term benefit and no evidence that they relieve symptoms of hearing loss. We found no evidence of benefit from treatment of OME with topical intranasal steroids, alone or in combination with an antibiotic, either at short or longer-term follow up.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-03-29 14:03:39 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-03-29 13:55:45 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-03-28 13:25:13 +0100" MODIFIED_BY="[Empty name]">
<P>This is one of a number of reviews of treatment options for patients with OME prepared within the Cochrane Ear, Nose and Throat Disorders Group.</P>
<P>Otitis media with effusion (OME), or 'glue ear', is characterised by an accumulation of fluid in the middle ear, in the absence of acute inflammation. It is an important and common problem. OME is the commonest cause of acquired hearing loss in childhood and may negatively effect language development (<LINK REF="REF-Haggard-1991" TYPE="REFERENCE">Haggard 1991</LINK>; <LINK REF="REF-Lous-1995a" TYPE="REFERENCE">Lous 1995a</LINK>; <LINK REF="REF-Lous-1995b" TYPE="REFERENCE">Lous 1995b</LINK>). OME is also associated with anxiety/depression and attention disorders and so may affect both children, their families and peers (<LINK REF="REF-Gouma-2010" TYPE="REFERENCE">Gouma 2010</LINK>). OME in early childhood has been shown to affect IQ, behaviour and reading into late teens (<LINK REF="REF-Bennett-2001" TYPE="REFERENCE">Bennett 2001</LINK>). The reason why the condition develops is uncertain, but low-grade infection, poor Eustachian tube function, allergy and adenoidal infection or hypertrophy have all been implicated (<LINK REF="REF-Chantzi-2005" TYPE="REFERENCE">Chantzi 2005</LINK>). OME often resolves spontaneously and return to normal middle ear function often occurs within three months (<LINK REF="REF-MRC-Multi_x002d_Centre-Otitis-Media-Study-Group-2001" TYPE="REFERENCE">MRC Multi-Centre Otitis Media Study Group 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Prevalence</HEADING>
<P>OME has a prevalence of about 20% at around two years of age with another peak at six years (<LINK REF="REF-Zielhuis-1990" TYPE="REFERENCE">Zielhuis 1990</LINK>). The prevalence of recurrent otitis media may be increasing (<LINK REF="REF-Lanphear-1997" TYPE="REFERENCE">Lanphear 1997</LINK>) and visits to the doctor for otitis media and otitis media with effusion have risen (from 9.9 million in 1975 to 24.5 million in 1990 in the US) (<LINK REF="REF-Schappert-1992" TYPE="REFERENCE">Schappert 1992</LINK>). Overall, the prognosis for OME is good, with over 50% of OME episodes resolving spontaneously within three months and 95% within one year. However, 30% to 40% of children have recurrent OME episodes and 5% of preschool children aged five years have persistent (longer than three months) bilateral hearing loss associated with OME (<LINK REF="REF-NICE-2008" TYPE="REFERENCE">NICE 2008</LINK>). Although the diagnosis of OME in primary care has increased over the last decade, the number of grommet operations performed in England and Wales fell from 43,300 in 1994-1995 to 25,442 in 2009-2010, primarily as a result of the &#8216;watchful waiting&#8217; strategy (<LINK REF="REF-HES-2010" TYPE="REFERENCE">HES 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cost</HEADING>
<P>The total annual cost of treating children under five for OME is over GBP 5000 million (EUR 4800) annually in the US (<LINK REF="REF-Gates-1996" TYPE="REFERENCE">Gates 1996</LINK>). The insertion of grommets (ventilation or tympanostomy tubes) is the second commonest surgical procedure in children, costing USD 1200 million (EUR 1100) annually in the US (<LINK REF="REF-Gates-1996" TYPE="REFERENCE">Gates 1996</LINK>). The full cost of ventilation tube insertion is estimated to be GBP 1208 in the UK and hearing aid treatment for OME is estimated to cost GBP 752 (<LINK REF="REF-NICE-2008" TYPE="REFERENCE">NICE 2008</LINK>). OME is a common reason for prescribing antibiotics that contributes to the growing problem of bacterial resistance.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diagnosis</HEADING>
<P>The recommended technique for diagnosing otitis media with effusion is impedance audiometry (tympanometry) in combination with otomicroscopy or pneumatic otoscopy (<LINK REF="REF-Bluestone-1988" TYPE="REFERENCE">Bluestone 1988</LINK>). OME is deemed to be present when the tympanometry results in a flat curve (relative gradient less than 0.1, type B), when mobility of the tympanic membrane is absent or reduced, or fluid or air bubbles are evident behind the ear drum. However, not all children with effusions suffer significant hearing loss. The positive predictive value for hearing loss of 25 dB or more of tympanometry characteristic of OME ranges from 49.0% to 66.4% (<LINK REF="REF-Dempster-1991" TYPE="REFERENCE">Dempster 1991</LINK>; <LINK REF="REF-Kazanas-1994" TYPE="REFERENCE">Kazanas 1994</LINK>; <LINK REF="REF-MRC-Multi_x002d_Centre-Otitis-Media-Study-Group-1999" TYPE="REFERENCE">MRC Multi-Centre Otitis Media Study Group 1999</LINK>). Tympanometry is therefore a surrogate measure for hearing loss associated with OME, and intervention decisions should ideally be made when hearing loss is documented (<LINK REF="REF-MRC-Multi_x002d_Centre-Otitis-Media-Study-Group-1999" TYPE="REFERENCE">MRC Multi-Centre Otitis Media Study Group 1999</LINK>).<BR/>
</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2010-11-23 10:38:36 +0000" MODIFIED_BY="[Empty name]">
<P>Many patients with OME require no specific treatment. The most common medical treatment options include the use of decongestants, mucolytics, steroids, antihistamines, antibiotics and auto-inflation. Surgical treatment options include grommet insertion, myringotomy (tympanocentesis, i.e. surgical incision of the ear drum, with or without aspiration of fluid from the middle ear cavity) and adenoidectomy. The optimal treatment strategy remains controversial, there being wide international variability in clinical practice. The UK National Institute for Health and Clinical Excellence (NICE) recommends active observation for three months before intervention is considered (<LINK REF="REF-NICE-2008" TYPE="REFERENCE">NICE 2008</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>There is in vitro and animal model evidence that steroids modulate effusions (<LINK REF="REF-Baggett-1997" TYPE="REFERENCE">Baggett 1997</LINK>; <LINK REF="REF-Tan-1997" TYPE="REFERENCE">Tan 1997</LINK>; <LINK REF="REF-Haddard-1998" TYPE="REFERENCE">Haddard 1998</LINK>; <LINK REF="REF-Yaman-2008" TYPE="REFERENCE">Yaman 2008</LINK>). It is hypothesised that steroids could clear effusions by: (a) stabilising membrane phospholipid breakdown and thus preventing the formation of arachidonic acid and associated inflammatory mediators; (b) shrinking peri-tubal lymphoid tissue; (c) enhancing secretion of Eustachian tube surfactant; and (d) reducing middle ear fluid viscosity (<LINK REF="REF-Rosenfeld-1992" TYPE="REFERENCE">Rosenfeld 1992</LINK>; <LINK REF="REF-Ducharme-2003" TYPE="REFERENCE">Ducharme 2003</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Topical intranasal steroids</HEADING>
<P>Topical intranasal steroids may be safer than systemic preparations because the glucocorticoid is rapidly degraded in the nasal mucosa to less active metabolites and any unchanged drug that is absorbed is metabolised in the first pass through the liver (<LINK REF="STD-Tracy-1998" TYPE="STUDY">Tracy 1998</LINK>). Systemic adverse effects are therefore less likely, while the desired anti-inflammatory effects may be similar.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral steroids</HEADING>
<P>Systemic steroids, however, may be able to gain access to the middle ear, while topical intranasal steroids would not be expected to reach the middle ear but may modulate Eustachian tube function. Clinicians may be concerned about using systemic steroids for what may be a self-limiting condition. However, short courses of oral corticosteroids are widely used to treat acute asthma in children and are usually well-tolerated. Side effects such as dyspepsia and behavioural disturbances are infrequent and resolve on drug withdrawal. There have been case reports of disseminated varicella infection in a child receiving short-term steroids for asthma (<LINK REF="REF-Wu-2008" TYPE="REFERENCE">Wu 2008</LINK>). Although long-term or frequent courses of oral steroids are associated with important adverse effects, repeated short courses of prednisolone (median of four courses in a year) in children with asthma were shown to be safe and not associated with any lasting effects on bone metabolism or mineralisation or adrenal function (<LINK REF="REF-Ducharme-2003" TYPE="REFERENCE">Ducharme 2003</LINK>). The National Institutes of Health (NIH) in the US advises that children who have not had chickenpox and periodically take oral corticosteroids should receive the varicella vaccine after they have been steroid-free for at least one month (<LINK REF="REF-NIH-2007" TYPE="REFERENCE">NIH 2007</LINK>).</P>
</SUBSECTION>
</THEORY>
<IMPORTANCE MODIFIED="2011-03-29 13:55:45 +0100" MODIFIED_BY="[Empty name]">
<P>Antibiotics, topical or systemic antihistamines, topical or systemic decongestants, topical or systemic corticosteroids, homeopathy, cranial osteopathy, acupuncture, dietary modification (including probiotics) and immunostimulants are not recommend for treating OME (<LINK REF="REF-Griffin-2006" TYPE="REFERENCE">Griffin 2006</LINK>; <LINK REF="REF-NICE-2008" TYPE="REFERENCE">NICE 2008</LINK>). Standard treatments for OME, such as hearing aids and ventilation tube insertion, are not trouble-free. Ventilation tube insertion involves a general anaesthetic. It is associated with an improvement in the mean hearing levels of 4 to 10 dB in children with bilateral tubes during the first six months of follow up but this diminishes with time (<LINK REF="REF-Browning-2010" TYPE="REFERENCE">Browning 2010</LINK>). Hearing aids can be uncomfortable and be associated with bullying and perceived stigma (<LINK REF="REF-Dengerink-1984" TYPE="REFERENCE">Dengerink 1984</LINK>). An alternative treatment, cheap and effective within primary care, would reduce secondary care referral and represent and important opportunity for cost saving to the health service and parents.</P>
<P>The effect of systemic and topical intranasal steroids on otitis media with effusion in children has been the subject of randomised and controlled clinical trials. At least three meta-analyses have addressed the topic and have found evidence for a 'steroid effect' (<LINK REF="REF-Nuss-1990" TYPE="REFERENCE">Nuss 1990</LINK>; <LINK REF="REF-Rosenfeld-1991" TYPE="REFERENCE">Rosenfeld 1991</LINK>; <LINK REF="REF-Stool-1994" TYPE="REFERENCE">Stool 1994</LINK>). All concluded that steroids cleared effusions more quickly in the short term. However, trials were often small and results of individual trials were contradictory. Nuss et al included trials published in abstract form only, whose quality could not be adequately assessed. One trial (<LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>) was not published when Rosenfeld and colleagues conducted their meta-analysis. Stool et al pooled a study of topical steroids with studies of systemic steroids. Since these three meta-analyses, two randomised controlled trials have examined the effect of topical intranasal steroids in OME (<LINK REF="STD-Tracy-1998" TYPE="STUDY">Tracy 1998</LINK>; <LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) and at least three other relevant trials involving oral steroids have been published (<LINK REF="STD-Rosenfeld-1995" TYPE="STUDY">Rosenfeld 1995</LINK>; <LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>). Existing systematic reviews have not examined topical steroid treatment separately. This systematic review updates existing studies and includes separate consideration of topical intranasal steroids.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-10-22 14:21:55 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the beneficial and harmful effects of treatment with steroids (both oral and topical intranasal) for children with hearing loss associated with otitis media with effusion. Our a priori hypothesis was that steroid treatment (oral or topical intranasal), either alone or in combination with another agent, is effective in treating the hearing loss associated with OME and in resolving effusions in children.</P>
<P>The primary outcomes sought were changes in hearing. Secondary outcomes were effect on effusions and adverse effects of treatment. As a minimum requirement, we expected studies to report short-term effects on effusions identified by a combination of pneumo-otoscopy or otomicroscopy and tympanometry.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-03-29 11:24:54 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-03-29 11:24:54 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-03-29 11:24:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials of oral and topical intranasal steroids. We included randomised studies that used non-intervention controls where blinding of outcome assessment was adequate. We excluded publications that were only available in abstract form since adequate appraisal was not possible; uncontrolled, non-randomised or retrospective studies; and studies reporting outcomes only with ears as the unit of analysis (rather than children) since observations made on the ears of a single child cannot be regarded as independent. In addition, we considered that if a 'single-ear view' of the whole child could not be extracted from the information provided, studies might be poor in other ways. Williams has shown that studies reporting outcomes by ear have larger effect sizes than studies using the child as the unit of analysis (<LINK REF="REF-Williams-1993" TYPE="REFERENCE">Williams 1993</LINK>). We made attempts to contact the authors of studies published only in abstract form for a full study report, and included these where obtained. We excluded studies (or data from arms of studies) comparing treatment with steroid plus additional treatment to treatment with placebo plus placebo because it was not possible to identify the 'steroid effect' from such data.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-11-23 12:00:11 +0000" MODIFIED_BY="[Empty name]">
<P>The focus was on studies of children up to the age of 12 years, and we report when older subjects were included. The age of the patients is pertinent in respect of both the natural history of the disease process and the measurable outcomes (see below).</P>
<P>We divided the studies into subgroups according to the following ways of assessing exposure:</P>
<P>1. The diagnosis of otitis media with effusion defined by:</P>
<P>A: Air-bone gap of 10 dB or more plus two or more of:<BR/>
</P>
<UL>
<LI>otomicroscopy</LI>
<LI>pneumatic otoscopy</LI>
<LI>tympanometry (type B and C2)</LI>
</UL>
<P>B: Two or more of:<BR/>
</P>
<UL>
<LI>otomicroscopy</LI>
<LI>pneumatic otoscopy</LI>
<LI>tympanometry (type B and C2)</LI>
</UL>
<P>C: One of otoscopy alone or tympanometry (type B and C2)</P>
<P>D: Poorly or not defined</P>
<P>2. Significant hearing loss defined by:</P>
<P>A: Pure-tone audiometry hearing loss of more than 20 dB at two or more times within three months (for example, mean of 500, 1000 and 2000 Hz hearing loss bilaterally)</P>
<P>B: Defined, but less strict than A</P>
<P>C: Uncertain or not defined</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-11-23 12:01:06 +0000" MODIFIED_BY="[Empty name]">
<P>Systemic or topical intranasal steroids compared with control (placebo or non-intervention control). We included additional treatments such as antibiotics so long as they were identical in the treatment and in the control groups. We grouped studies according to the comparisons made: (1) oral steroid versus control; (2) oral steroid plus additional treatment versus control plus identical additional treatment; (3) topical intranasal steroid versus control; and (4) topical intranasal steroid plus additional treatment versus control plus identical additional treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-03-28 13:27:10 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-03-28 13:26:34 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Differences in hearing level.</LI>
<LI>Degree of conductive hearing loss (assessment of air-bone gaps).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-03-28 13:27:10 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Duration of hearing loss.</LI>
<LI>Presence or absence of fluid in the middle ear cavity: short (&lt; one month), intermediate (one to &lt; six months) and longer term (&#8805; six months).</LI>
<LI>Symptom score.</LI>
<LI>Developmental outcomes, such as language development and behaviour.</LI>
<LI>Possible adverse effects (for example, evidence of immunosuppression, abdominal pain, atrophy of the nasal mucosa, epistaxis, changes in behaviour).</LI>
<LI>Cost-effectiveness data.</LI>
</OL>
<P>N.B. Where a study reported results at multiple follow-up periods, we only used the data relating to the longest follow-up period (or closest to the upper limit for short, intermediate and long) in the analysis. We considered duration of follow up, where feasible, from randomisation not treatment completion.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-03-28 13:27:49 +0100" MODIFIED_BY="[Empty name]">
<P>We conducted systematic searches for randomised controlled trials. There were no language, publication year or publication status restrictions. The date of the last search was 26 August 2010, following a previous update search in March 2005.</P>
<ELECTRONIC_SEARCHES MODIFIED="2011-03-28 13:27:49 +0100" MODIFIED_BY="[Empty name]">
<P>For the update of this review we searched: the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2010, Issue 3); PubMed; EMBASE; CINAHL; LILACS; KoreaMed; IndMed; PakMediNet; CAB Abstracts; Web of Science; BIOSIS Previews; CNKI; ISRCTN; ClinicalTrials.gov; ICTRP and Google.</P>
<P>We modelled subject strategies for databases on the search strategy designed for CENTRAL. Although the strategy was specific to otitis media with effusion, we did not restrict it to children nor did we attempt to exclude acute otitis media in case this excluded material of relevance. Where appropriate, we combined subject strategies with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in the<I> Cochrane Handbook for Systematic Reviews of Interventions </I>Version 5.0.2, Box 6.4.b. (<A HREF="http://archie.cochrane.org/sections/documents/view?document=274799071911441632&amp;format=REVMAN#REF-Handbook-2009#REF-Handbook-2009">Handbook 2009</A>)). Search strategies for the major databases including CENTRAL are provided in <A HREF="http://archie.cochrane.org/sections/documents/view?document=274799071911441632&amp;format=REVMAN#APP-01#APP-01">Appendix 1</A>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-02-04 15:15:32 +0000" MODIFIED_BY="[Empty name]">
<P>We scanned reference lists of identified studies for further trials. We searched PubMed, TRIPdatabase, NHS Evidence - ENT and Audiology, and Google to retrieve existing systematic reviews possibly relevant to this systematic review, in order to search their reference lists for additional trials. We sought abstracts from conference proceedings via the Cochrane Ear, Nose and Throat Disorders Group Trials Register. In previous searches in 2005, we also wrote to experts asking about knowledge of additional studies for the review.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-03-28 13:35:11 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-11-23 12:06:55 +0000" MODIFIED_BY="[Empty name]">
<P>We carried out searches independently. We assessed the full text of all studies loosely meeting the inclusion criteria independently and resolved differences of opinion regarding inclusion by consensus, or by using a third party in the face of ongoing disagreement.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-03-28 13:34:51 +0100" MODIFIED_BY="[Empty name]">
<P>We independently extracted data from the published reports using standardised data extraction forms. Disagreement was resolved by consensus or referral to a third party after returning to the original publication. For each trial, we documented the following aspects:</P>
<OL>
<LI>methods (including methods of allocation, blinding, study structure);</LI>
<LI>participants (including ages, setting, inclusion criteria, prospective or retrospective documentation of effusions prior to allocation, method of diagnosis);</LI>
<LI>interventions (including dosages, duration, care in matching placebo and active treatment); and</LI>
<LI>outcomes (including definitions of cure, hearing and language assessments and adverse effects of treatment).</LI>
</OL>
<P>In studies that provided data for various definitions of cure, we used data for the strictest definition. In studies with a cross-over design, where patients who did not have OME resolution at follow up were given the alternative treatment, we did not use data from the cross-over treatment period. Similarly, in multi-arm studies (e.g. steroid versus antibiotic versus non-steroidal anti-inflammatory versus control), we only used data for the steroid-treated and control groups.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-03-28 13:34:44 +0100" MODIFIED_BY="[Empty name]">
<P>We independently assessed the risk of bias of the included studies using the scheme described in the <I>Cochrane Handbook for Systematic Review of Interventions</I> (<LINK REF="REF-Handbook-2011" TYPE="REFERENCE">Handbook 2011</LINK>). This involved assessing studies for:</P>
<OL>
<LI>selection bias (presence or absence of adequate sequence generation and allocation concealment);</LI>
<LI>performance bias (presence or absence of blinding of patients and outcome assessors);</LI>
<LI>attrition bias (losses to follow up); and</LI>
<LI>detection bias (quality of outcome assessment and selective reporting of results).</LI>
</OL>
<P>We used the Cochrane &#8216;Risk of bias&#8217; tool in RevMan 5.1 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>), which involved describing each of these domains as reported in the trial and then assigning a judgement about the adequacy of each entry. This involved making a prespecified judgement of 'high', 'low' or 'unclear' risk of bias.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-03-28 13:35:11 +0100" MODIFIED_BY="[Empty name]">
<P>We used the statistical methods for dichotomous outcomes described by Yusuf et al (<LINK REF="REF-Yusuf-1985" TYPE="REFERENCE">Yusuf 1985</LINK>). Results were expressed as a risk ratio (RR) for achieving the outcome in question at a given point in time together with the 95% confidence interval (CI) for this estimate. We decided to use RRs rather than odds ratios (ORs) as they are easier to interpret and consistent with general intuition (<LINK REF="REF-Davies-1998" TYPE="REFERENCE">Davies 1998</LINK>). We presented continuous data using the weighted mean difference (and 95% CI). We pooled studies using a random-effects method. We were interested in the broad perspective of whether steroid treatment (systemic or intranasal and with or without antibiotics) is beneficial for treating OME in children. We were therefore interested in the average effect of the intervention across clinically diverse studies, which represented the different mix of participants and implementations of the interventions that we wanted our results to be generalisable to. We assessed statistical heterogeneity between studies using the Chi² test, the I² statistic and visual inspection of the forest plots. When this was present we tried to investigate the reasons for the heterogeneity (including methodological factors or outcome assessment), but the small number of included studies precluded the use meta-regression or subgroup analyses. When considerable heterogeneity (i.e. I² ranged from 75% to 100%) (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>) was present and there was inconsistency in the direction of the results then pooling was not considered appropriate (the P value of the Chi² test and width of the CIs were also taken into consideration when making this interpretation).</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-03-29 14:03:39 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-03-29 14:03:39 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2011-03-28 13:35:34 +0100" MODIFIED_BY="[Empty name]">
<P>We updated the searches for the review in September 2009 and August 2010. The searches retrieved a total of 45 references; we considered four to be potentially relevant and obtained the full-text papers. Following review of the full text we included one new study in the review (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) and excluded a further three (<LINK REF="STD-Ortega-del-Alamo-2005" TYPE="STUDY">Ortega del Alamo 2005</LINK>; <LINK REF="STD-Cengel-2006" TYPE="STUDY">Cengel 2006</LINK>; <LINK REF="STD-Choung-2008" TYPE="STUDY">Choung 2008</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-03-29 14:03:39 +0100" MODIFIED_BY="[Empty name]">
<P>Nine studies involved assessment of oral steroids (<LINK REF="STD-Schwartz-1980" TYPE="STUDY">Schwartz 1980</LINK>; <LINK REF="STD-Niederman-1984" TYPE="STUDY">Niederman 1984</LINK>; <LINK REF="STD-Macknin-1985" TYPE="STUDY">Macknin 1985</LINK>; <LINK REF="STD-Lambert-1986" TYPE="STUDY">Lambert 1986</LINK>; <LINK REF="STD-Berman-1990" TYPE="STUDY">Berman 1990</LINK>; <LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>; <LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>; <LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>) and three studies involved assessment of topical intranasal steroids (<LINK REF="STD-Shapiro-1982" TYPE="STUDY">Shapiro 1982</LINK>; <LINK REF="STD-Tracy-1998" TYPE="STUDY">Tracy 1998</LINK>; <LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>). One study was open, comparing children treated with steroids to non-intervention controls (<LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Description of participants</HEADING>
<P>Most studies (both of oral and topical intranasal steroids) documented effusions by a combination of pneumatic otoscopy and tympanometry (1B). No study documented hearing loss from OME two or more times in the three months prior to study entry (2A). Only one study required documented hearing loss for all children prior to study entry (<LINK REF="STD-Macknin-1985" TYPE="STUDY">Macknin 1985</LINK>). Three studies included children older than 12 years: two studies included children aged up to 14 years (<LINK REF="STD-Niederman-1984" TYPE="STUDY">Niederman 1984</LINK>; <LINK REF="STD-Macknin-1985" TYPE="STUDY">Macknin 1985</LINK>) and one study included children up to 15 years (<LINK REF="STD-Lambert-1986" TYPE="STUDY">Lambert 1986</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Description of interventions</HEADING>
<P>For oral steroids, six studies evaluated the use of prednisolone (<LINK REF="STD-Schwartz-1980" TYPE="STUDY">Schwartz 1980</LINK>; <LINK REF="STD-Lambert-1986" TYPE="STUDY">Lambert 1986</LINK>; <LINK REF="STD-Berman-1990" TYPE="STUDY">Berman 1990</LINK>; <LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>; <LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>) at doses ranging from one (<LINK REF="STD-Schwartz-1980" TYPE="STUDY">Schwartz 1980</LINK>; <LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>; <LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>) to up to two (<LINK REF="STD-Berman-1990" TYPE="STUDY">Berman 1990</LINK>) mg/kg/day for a duration of seven (<LINK REF="STD-Berman-1990" TYPE="STUDY">Berman 1990</LINK>) to 14 days (<LINK REF="STD-Lambert-1986" TYPE="STUDY">Lambert 1986</LINK>; <LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>; <LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>). Two studies used dexamethasone 0.15 mg/kg in tapering doses for two weeks (<LINK REF="STD-Niederman-1984" TYPE="STUDY">Niederman 1984</LINK>; <LINK REF="STD-Macknin-1985" TYPE="STUDY">Macknin 1985</LINK>). One study evaluated the use of a single dose of betamethasone (6 mg) given on day 10 of the antibiotic treatment (<LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>).</P>
<P>For topical intranasal steroids, one study used dexamethasone (one spray in each nostril three times a day) for three weeks (<LINK REF="STD-Shapiro-1982" TYPE="STUDY">Shapiro 1982</LINK>), one study used beclomethasone (two sprays in each nostril twice a day) for 12 weeks (<LINK REF="STD-Tracy-1998" TYPE="STUDY">Tracy 1998</LINK>), and one study used mometasone furoate (one spray in each nostril once a day) for three months (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Audiometry</HEADING>
<P>Six included studies provided audiometry data at follow up (<LINK REF="STD-Macknin-1985" TYPE="STUDY">Macknin 1985</LINK>; <LINK REF="STD-Lambert-1986" TYPE="STUDY">Lambert 1986</LINK>; <LINK REF="STD-Berman-1990" TYPE="STUDY">Berman 1990</LINK>; <LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>; <LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>), but only three provided data that could be used in this review (numbers of children with partial or no improvement on audiometric evaluation by <LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>; numbers of children improving their hearing loss by at least 10 dB by <LINK REF="STD-Macknin-1985" TYPE="STUDY">Macknin 1985</LINK> and pass/fail of audiometry sweep at 25 dB HL by <LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>). (The definition of hearing loss was not clear for <LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>, but this was the only study included in the analysis for steroid plus antibiotic). Audiometry data in the remaining studies used ears as the unit of analysis. One study (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) also reported median number of days with hearing loss (for the purpose of this review median has been assumed to be the same as the mean).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Presence of OME</HEADING>
<P>All 12 studies provided data on the resolution of OME at follow up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Symptoms and language development</HEADING>
<P>Only two studies used symptoms as an outcome (<LINK REF="STD-Tracy-1998" TYPE="STUDY">Tracy 1998</LINK>; <LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>). One (<LINK REF="STD-Tracy-1998" TYPE="STUDY">Tracy 1998</LINK>), a study of topical intranasal steroid plus antibiotic versus placebo plus antibiotic, reported on symptoms in the form of a scale that was considered as continuous data. The validation of the symptom scale was not described. The second (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>), which compared intranasal steroid with placebo, collected data on seven symptoms using diaries but did not report the findings. The study also used a condition-specific functional scale (OM8-30) developed by the Medical Research Council (MRC). However, most of the results relating to this scale were reported as unusable box plots (based on medians and inter quartile ranges) and P values relating to non-significant findings.</P>
<P>Only one study (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) reported effects on language or other aspects of development, which was one of the domains of the OM8-30 used. However, the results were not presented in a usable format.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>Adverse effects of steroid treatment were reported in five studies of oral therapy (<LINK REF="STD-Niederman-1984" TYPE="STUDY">Niederman 1984</LINK>; <LINK REF="STD-Macknin-1985" TYPE="STUDY">Macknin 1985</LINK>; <LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>; <LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>) and three studies of topical therapy (<LINK REF="STD-Shapiro-1982" TYPE="STUDY">Shapiro 1982</LINK>; <LINK REF="STD-Tracy-1998" TYPE="STUDY">Tracy 1998</LINK>; <LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cost-effectiveness data</HEADING>
<P>Only one study (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) included an economic evaluation. The main outcome measure was the incremental cost per quality-adjusted life-year (QALY) gained for topical steroids compared with placebo. There was no evidence that intranasal steroids are a cost-effective use of UK National Health Service (NHS) resources for treating OME. Children receiving topical steroids accrued slightly, but not statistically significant, higher costs (incremental cost/child: £11 pound, 95% CI -199 to 222) and non-statistically significantly fewer QALYs (incremental QALY gain/child: -0.0166, 95% CI -0.0652 to 0.0320) than those receiving placebo. Topical steroids had a 24.19% probability of being cost-effective at a GBP 20,000 per QALY gained threshold, a 23.82% probability of being more effective and a 46.25% probability of being less costly.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">General</HEADING>
<P>In cases in which the same data apparently appear twice (<LINK REF="STD-Schwartz-1980" TYPE="STUDY">Schwartz 1980</LINK> and <LINK REF="STD-Schwartz-1981" TYPE="STUDY">Schwartz 1981</LINK>; Giebink 1988 and <LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>), these data are used only once in this review.</P>
<P>Studies fell into four categories:</P>
<UL>
<LI>oral steroids versus control;</LI>
<LI>oral steroids plus antibiotic versus control plus antibiotic;</LI>
<LI>topical intranasal steroid versus control; and</LI>
<LI>topical intranasal steroid plus antibiotic versus control plus antibiotic or antibiotic alone.</LI>
</UL>
<P>The longest follow up was for nine months (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-03-28 13:38:24 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded a total of 10 studies for the following reasons: published in only abstract form (<LINK REF="STD-Woodhead-1986" TYPE="STUDY">Woodhead 1986</LINK>; <LINK REF="STD-Heary-1990" TYPE="STUDY">Heary 1990</LINK>); non-randomised (<LINK REF="STD-Persico-1978" TYPE="STUDY">Persico 1978</LINK>; <LINK REF="STD-Rosenfeld-1995" TYPE="STUDY">Rosenfeld 1995</LINK>); used ears instead of patients as the unit of analysis (<LINK REF="STD-Cengel-2006" TYPE="STUDY">Cengel 2006</LINK>); compared antibiotic plus steroid with non placebo control (<LINK REF="STD-Schwartz-1981" TYPE="STUDY">Schwartz 1981</LINK>); compared antibiotic plus steroid with placebo plus placebo (<LINK REF="STD-Berman-1987" TYPE="STUDY">Berman 1987</LINK>; <LINK REF="STD-Daly-1991" TYPE="STUDY">Daly 1991</LINK>); compared antibiotic plus steroid with antibiotic only and did not report blind outcome assessment (<LINK REF="STD-Choung-2008" TYPE="STUDY">Choung 2008</LINK>); and did not evaluate steroid (<LINK REF="STD-Ortega-del-Alamo-2005" TYPE="STUDY">Ortega del Alamo 2005</LINK>).</P>
<P>See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-03-29 11:24:12 +0100" MODIFIED_BY="[Empty name]">
<P>The overall quality of the included studies was generally fairly high (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, 'Risk of bias' graph and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, 'Risk of bias' summary) although methodological issues were poorly reported. Most studies were described as double-blind, randomised controlled trials, but very few (4/12) reported their method of sequence generation. It was not possible to judge whether an adequate method was used to conceal allocation for two of the nine studies that evaluated oral steroids (<LINK REF="STD-Lambert-1986" TYPE="STUDY">Lambert 1986</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>) and one of the three studies that evaluated topical steroids (<LINK REF="STD-Shapiro-1982" TYPE="STUDY">Shapiro 1982</LINK>), although both used a placebo control; the remaining studies used adequate allocation concealment. Most studies did not include drop-outs or missing data in their analyses, with loss to follow up being greater than 10% in three studies (<LINK REF="STD-Niederman-1984" TYPE="STUDY">Niederman 1984</LINK>; <LINK REF="STD-Berman-1990" TYPE="STUDY">Berman 1990</LINK>; <LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) (range 15% to 24%). Two further studies (<LINK REF="STD-Schwartz-1981" TYPE="STUDY">Schwartz 1981</LINK>; <LINK REF="STD-Lambert-1986" TYPE="STUDY">Lambert 1986</LINK>) reported the number of participants included in the analyses, but it was unclear if this was the same as the number of participants initially randomised.</P>
<SUBSECTION>
<HEADING LEVEL="3">Oral steroids</HEADING>
<P>In the study by Podoshin (oral steroid plus antibiotic versus placebo plus antibiotic) the reporting of outcomes were confusing: 'success' is defined as normal otoscopy, tympanometry and closure of the air-bone gap, yet outcomes for 'complete improvement' are given according to audiometry and tympanometry separately (<LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>).</P>
<P>Giebink and colleagues used an open design because treatment regimens differed and placebo control was not feasible (<LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>). However, treatment allocation was remote (concealed) and objective outcome measures used. Percentages of children followed up (rather than absolute numbers) were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical intranasal steroids</HEADING>
<P>In the trial of topical intranasal steroids plus antibiotic versus control plus antibiotic, Tracy and colleagues pooled data for children treated with antibiotics plus placebo and children treated with antibiotics alone (<LINK REF="STD-Tracy-1998" TYPE="STUDY">Tracy 1998</LINK>). These groups had similar outcomes, therefore we present these pooled data.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-03-28 13:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>Overall the numbers of studies for each comparison were small (ranged from one to five). The number of participants available for each comparison ranged from 15 to 409.</P>
<SUBSECTION>
<HEADING LEVEL="3">Oral steroids versus control</HEADING>
<P>Three included studies provided data on a total of 108 patients randomised to treatment with oral steroids versus placebo (<LINK REF="STD-Niederman-1984" TYPE="STUDY">Niederman 1984</LINK>; <LINK REF="STD-Macknin-1985" TYPE="STUDY">Macknin 1985</LINK>) or no-treatment control (<LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>Only one study included usable data on our primary outcome measure, hearing loss (<LINK REF="STD-Macknin-1985" TYPE="STUDY">Macknin 1985</LINK>). The results did not show benefit from using oral steroids compared with placebo, in terms of hearing not improved by at least 10 dB in either ear at six weeks follow up (risk ratio (RR) 1.09; 95% confidence interval (CI) 0.80 to 1.49, 44 children) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>Two studies reported data on OME resolution, for which the findings did not show a significant effect of steroids compared to placebo or no intervention control at short-term follow up (two weeks) (RR 3.80; 95% CI 0.93 to 15.52, three trials, 108 children) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) and intermediate-term follow up (four to six weeks) (RR 1.54; 95% CI 0.76 to 3.14, three trials, 106 children) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). These findings were based on a random-effects model. The summary effect size at short-term follow up is large with a wide CI that only just crossed zero. When analysing the same data using a fixed-effect model, the results showed oral steroids to be significantly better than the control (RR 4.48; 95% CI 1.52 to 13.23). Although the studies were clinically heterogeneous, statistical between-study heterogeneity for this comparison was fairly low (Chi² 2.75, df = 2, P = 0.25; I² = 27%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral steroids plus antibiotics versus control plus antibiotics</HEADING>
<P>Six included studies provided data on a total of 508 patients randomised to treatment with oral steroids plus antibiotic versus placebo plus antibiotic.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>Four studies (<LINK REF="STD-Lambert-1986" TYPE="STUDY">Lambert 1986</LINK>; <LINK REF="STD-Berman-1990" TYPE="STUDY">Berman 1990</LINK>; <LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>) included audiometry data, but only one reported data that could be used in the analysis (<LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>). There was no significant difference between the intervention groups in terms of the number of participants with partial or no improvement in hearing loss (RR 1.01; 95% CI 0.73 to 1.40; 99 children) at two months follow up (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>The RR for OME resolution at short-term follow up (seven to 28 days) was 1.99 (95% CI 1.14 to 3.49, five trials, 409 children) in favour of the steroid group (<LINK REF="STD-Schwartz-1980" TYPE="STUDY">Schwartz 1980</LINK>; <LINK REF="STD-Lambert-1986" TYPE="STUDY">Lambert 1986</LINK>; <LINK REF="STD-Berman-1990" TYPE="STUDY">Berman 1990</LINK>; <LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). However, there was significant heterogeneity between these studies (P &lt; 0.01, I² = 69%). One study reported inconsistent results that were in favour of the control group, but the summary effect estimate was very close to zero (RR 0.88; 95% CI 0.51 to 1.50) and therefore not considered to be inconsistent enough to prevent pooling. There was no clear reason as to why this study would report inconsistent findings, although the study was poorly reported and included slightly older children, ranging from two to 15 years (mean six years). Removing this potential outlier resulted in homogeneity between the remaining studies (<LINK REF="STD-Lambert-1986" TYPE="STUDY">Lambert 1986</LINK>) (Tau² = 0.00; Chi² = 2.86, df = 3 (P = 0.41); I² = 0%) and an increase in the effect size and its precision (RR 2.39; 95% CI 1.69 to 3.37, four trials, 349 children). Two studies (<LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>) reported data on intermediate follow up for which there was a non-significant benefit in favour of the steroid group for OME resolution at one to two months (RR 1.44; 95% CI 0.97 to 2.13, two trials, 231 children) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). Only one study (<LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>) reported long-term (six months) outcome data on resolution of OME but only provided this data for a subset of 15 (13%) patients who were considered cured at prior follow-up visits.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical intranasal steroids versus control</HEADING>
<P>Two included studies provided data on a total of 238 patients randomised to treatment with intranasal steroids versus placebo (<LINK REF="STD-Shapiro-1982" TYPE="STUDY">Shapiro 1982</LINK>; <LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>One study (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) included audiometry data. There was no important difference between the groups for median days hearing loss (weighted mean difference (WMD) 0.0; 95% CI -4.51 to 4.51, 200 children) at three months follow up (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>) or the number of participants failing the audiometry test (fail on more than two frequencies in both ears at 0.5, 1, 2, 3 and 4 kHz using hand-held audiometers at 25 dB HL) (RR 1.17; 95% CI 0.87 to 1.58; 141 children) at nine months follow up (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>There was no evidence of improvement in OME resolution with the use of intranasal steroid at short-term follow up (three weeks) (RR 0.64; 95% CI 0.31 to 1.31, one trial, 44 children) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>) (<LINK REF="STD-Shapiro-1982" TYPE="STUDY">Shapiro 1982</LINK>). There was also no important difference between the intervention groups for OME resolution at intermediate follow up (three months) (RR 1.11; 95% CI 0.85 to 1.46, one trial, 172 children) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>) (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) or long-term follow up (nine months) (RR 0.85; 95% CI 0.65 to 1.11, one trial, 144 children) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>) (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical intranasal steroids plus antibiotics versus control plus antibiotics</HEADING>
<P>There was only one study that compared topical intranasal steroids plus antibiotics with placebo plus antibiotics (<LINK REF="STD-Tracy-1998" TYPE="STUDY">Tracy 1998</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>No study of topical intranasal steroids included audiometry data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>One study (<LINK REF="STD-Tracy-1998" TYPE="STUDY">Tracy 1998</LINK>) reported data on OME resolution at intermediate follow up, for which there was no important difference between the steroid and the control group at three months (RR 1.26; 95% CI 0.54 to 2.96, 53 children) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). The study also included data on a symptom score used after three months, which also showed no overall benefit of using steroid (WMD -4.5; 95% CI -10.28 to 1.28, 39 children) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>Only four studies (<LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>; <LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>; <LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) reported the actual number and type of adverse effects experienced; one (<LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>) only included haematological adverse effects. There were no significant differences between oral steroid plus antibiotic and oral placebo plus antibiotic (RR 1.34; 95% CI 0.84 to 2.14, two trials, 255 children) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) (<LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>) or intranasal steroid and placebo (RR 1.26; 95% CI 0.80 to 1.99, 172 children) (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>) (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) for adverse effects. In the studies by Shapiro and Giebink transient drops in cortisol levels were measured in steroid-treated patients. Other studies mentioned the following mild to moderate adverse effects: vomiting, diarrhoea, stomach ache, gastroenteritis, dermatitis, increased appetite, hyperactivity, rash transient nasal stinging epistaxis, nosebleed, dry throat and cough.</P>
<P>Only one study (<LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>) reported that some patients had to discontinue treatment due to adverse effects, although none appear to be associated with steroid treatment. Treatment was divided into two phases, an initial two-week period of steroid plus antibiotic versus placebo plus antibiotic, and then a second two-week phase that evaluated prolonged antibiotic treatment. During phase I placebo was discontinued due to adverse effects in two participants and in phase II amoxicillin or placebo was discontinued due to adverse effects in three participants (two in the steroid and one in the placebo + antibiotic group). The actual severity of the adverse effects was not reported, but could be considered potentially serious. (Only data on adverse effects from phase I that included the steroid treatment are included in the meta-analysis). No serious or lasting adverse effects were reported in the remaining four studies on oral steroids mentioning adverse effects (<LINK REF="STD-Niederman-1984" TYPE="STUDY">Niederman 1984</LINK>; <LINK REF="STD-Macknin-1985" TYPE="STUDY">Macknin 1985</LINK>; <LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>; <LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>; <LINK REF="STD-Mandel-2002" TYPE="STUDY">Mandel 2002</LINK>) or in the three studies on topical intranasal steroids (<LINK REF="STD-Shapiro-1982" TYPE="STUDY">Shapiro 1982</LINK>; <LINK REF="STD-Tracy-1998" TYPE="STUDY">Tracy 1998</LINK>; <LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">General</HEADING>
<P>Our objectives were to assess whether the average effect of steroids for OME is beneficial, which is a much broader perspective than that of individual studies that assess the use of a specific steroid intervention in a narrow patient population. We also wanted to able to generalise the findings to a range of scenarios. As such our review included a clinically diverse set of studies that differed in terms of pharmacological interventions including the steroid formulation, steroid dose, duration of steroid treatment and concomitant antibiotic; and study population including age, setting, proportion with bilateral OME and duration of OME at study entry. However, we deemed the studies to have enough in common for it to make sense to synthesise the data, and statistical heterogeneity was not considerable.</P>
<P>Ten comparisons across the study groups included only one study, so they offer no new information. Overall, seven comparisons favoured steroids, six favoured controls and two favoured neither. However, the confidence intervals were generally wide and included unity for all but one comparison. There were a small number of studies in many of the comparisons, therefore risk of bias was not used in sensitivity analyses.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-03-28 13:46:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Oral steroids</HEADING>
<P>There was no evidence of the beneficial effect of oral steroids (with or without antibiotics) on hearing loss associated with otitis media with effusion (OME). However, this outcome was only evaluated by two studies of small (oral steroids) to moderate size (oral steroids plus antibiotics). One study also included patients with unilateral hearing loss and the other did not state how many had bilateral or unilateral hearing loss. Only one study required documented hearing loss for all children prior to study entry.</P>
<P>Children treated with a steroid used together with an antibiotic were twice as likely to have improved resolution of their effusion as those treated with antibiotics plus placebo in the short term (up to two weeks post-randomisation: risk ratio (RR) 1.99; 95% confidence interval (CI) 1.14 to 3.49). However, the beneficial effect of steroids was no longer statistically significant (RR 1.44; 95% CI 0.97 to 2.13) at intermediate follow up (up to two months after randomisation), although the meta-analysis only included two studies (231 children).</P>
<P>Oral steroids, when used alone, also appear to have a beneficial effect on the resolution of OME in the short term. Using a random-effects model, children who were treated with oral steroids were over three times more likely to have an improved resolution of effusion than those treated with placebo, but the confidence interval was wide and included unity (RR 3.80; 95% CI 0.93 to 15.52). However, when a fixed-effect model was used to pool the same data the findings became statistically significant. Although the clinical heterogeneity between studies means that a random-effects model was appropriate, there was no statistical heterogeneity present and the findings of the fixed-effect model demonstrates the potential effectiveness of oral steroids for OME resolution in the short term. However, the beneficial effect of oral steroids, as with the steroids plus antibiotics, was no longer statistically significant (RR 1.54; 95% CI 0.76 to 3.14) at intermediate follow up (up to six weeks after randomisation) but the meta-analysis was based on fewer than 100 children (three studies).</P>
<P>Few data were available for longer-term outcomes. One study (<LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>) reported six-month data on OME resolution, but only provided these data for a subset of 15 (13%) patients who were considered cured at prior follow-up visits. No study assessed the effect of steroids on hearing or speech in the longer term.</P>
<P>Data concerning adverse effects were provided in five studies. No lasting or serious adverse effects were reported. However, the numbers of children involved are insufficient to judge safety in pragmatic settings and no long-term data were available. Furthermore, we only included randomised controlled trials in our review, which is not the optimum study design for evaluating adverse effects, especially if they are uncommon or long-term.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical nasal steroids</HEADING>
<P>Given concern about treating what is often a self-limiting condition with systemic steroids, we were particularly interested to examine evidence for the effectiveness of topical intranasal steroids. The two studies we included of topical intranasal steroid and the one study of topical intranasal steroids in combination with an antibiotic showed no benefit in the short, intermediate or long term.</P>
<P>Only one study (<LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>), which compared topical intranasal steroid with placebo, reported on hearing loss, for which there was no benefit. The same study also reported long-term data on speech and language, which was part of a subscale of the condition-specific outcome scale OM8-30. However, the findings were reported in a format we could not use for this review and so could not be included in our analyses.</P>
<P>All three studies mentioned adverse effects. No lasting or serious adverse effects were found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">General</HEADING>
<P>No study documented hearing loss prospectively prior to study entry. Seven studies included audiometry data in their outcomes, but hearing loss results of only three studies (<LINK REF="STD-Macknin-1985" TYPE="STUDY">Macknin 1985</LINK>; <LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>; <LINK REF="STD-Williamson-2009" TYPE="STUDY">Williamson 2009</LINK>) could be used in this review. Steroid treatment did not improve hearing loss. Only two studies attempted to measure the effect of steroids on subjective symptoms.</P>
<P>Comparing our results to previous reviews, Nuss and Berman (<LINK REF="REF-Nuss-1990" TYPE="REFERENCE">Nuss 1990</LINK>) included studies published in abstract form only (<LINK REF="STD-Heary-1990" TYPE="STUDY">Heary 1990</LINK>) and a non-randomised, open study (<LINK REF="STD-Persico-1978" TYPE="STUDY">Persico 1978</LINK>). They concluded that combination therapy (oral steroids plus antibiotics) is worth considering in children with OME persisting beyond eight weeks prior to surgical intervention. Rosenfeld and colleagues (<LINK REF="REF-Rosenfeld-1991" TYPE="REFERENCE">Rosenfeld 1991</LINK>) performed a meta-analysis of six randomised trials, and concluded that children receiving oral steroids for seven to 14 days were three times more likely than control subjects to have both ears free of effusion at the end of therapy (95% CI 2.2 to 4.1). They also found significant heterogeneity between studies. Three of the studies involved treatment with oral steroid plus antibiotic (odds ratio (OR) favouring steroid plus antibiotic treatment 2.8; 95% CI 2.0 to 4.0) and three oral steroid alone (OR favouring steroids 3.7; 95% CI 2.0 to 6.7). These authors concluded that despite favourable ORs for short-term resolution of effusions, they could not recommend the use of steroids for OME until more is known about which children are most likely to derive benefit. The difference between these reviews and the results we obtained are accounted for by the inclusion of a study published after their analysis was done (<LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>). We considered clinical effectiveness. Berman and colleagues performed a meta-analysis of clinical effectiveness to establish cost-effectiveness of treatment for OME (<LINK REF="REF-Berman-1994" TYPE="REFERENCE">Berman 1994</LINK>). In comparing steroid plus antibiotic, they included two trials that did not meet our inclusion criteria (<LINK REF="STD-Berman-1987" TYPE="STUDY">Berman 1987</LINK>; <LINK REF="STD-Daly-1991" TYPE="STUDY">Daly 1991</LINK>). They concluded that steroid plus antibiotic was the most cost-effective intervention to clear bilateral middle ear effusion for children at a first follow-up visit six weeks after diagnosis of acute otitis media. However, they did not consider risks, adverse effects and parental preferences. The meta-analysis for the Agency for Health Care Policy and Research (AHCPR) used Bayesian statistical methods (<LINK REF="REF-Stool-1994" TYPE="REFERENCE">Stool 1994</LINK>). Based on the same studies we included for oral steroids compared to control, they found a mean difference in OME at two weeks of 18.4% (95% CI -3.4% to 38.6%) favouring steroid therapy. By four to six weeks the difference in improvement was 4.5% (95% CI -11.7% to 20.6%). Comparing oral steroid plus antibiotic to antibiotic, they included the trial by Podoshin (<LINK REF="STD-Podoshin-1990" TYPE="STUDY">Podoshin 1990</LINK>) but the trial by Hemlin (<LINK REF="STD-Hemlin-1997" TYPE="STUDY">Hemlin 1997</LINK>) was not yet published. They found a mean improvement for antibiotic steroid combination compared to antibiotic alone of 25.1% (95% CI -1.3% to 49%) that was not statistically significant. They also did a comparison of steroids plus antibiotic compared to control and included a trial of topical nasal steroids in this comparison; they found a mean improvement of OME due to steroid plus antibiotic therapy of 21.4% (95% CI -1.4% to 42.6%) that was not statistically significant. We did not carry out this comparison since treatment arms differed more than by steroid alone. The AHCPR recommended that steroids should not be used for OME. The UK National Institute for Health and Clinical Excellence (NICE) recommends against intranasal steroid treatment for OME (<LINK REF="REF-NICE-2008" TYPE="REFERENCE">NICE 2008</LINK>).</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>There is no evidence of beneficial effect from steroids (oral or topical) on hearing loss associated with OME. There is some evidence demonstrating short-term improvement of OME from oral steroids, especially when used in combination with antibiotics. However, we found no evidence for lasting beneficial effect on effusions from oral or topical intranasal steroid treatment, and no short-term benefit from intranasal steroids.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-11-23 12:51:11 +0000" MODIFIED_BY="[Empty name]">
<P>OME may be present without significant hearing loss and there is a high rate of spontaneous recovery from the hearing loss associated with OME, so future studies should document hearing loss associated with OME for a period prior to beginning study treatment and at follow up. In the absence of evidence that unilateral OME influences language development, the practice of either treating in routine clinical practice or entering children with unilateral OME into treatment research studies is questionable. Follow up should be longer and ideally include symptom, or quality of life, and hearing assessments. Audiometry data should be presented not as mean hearing levels for groups but as numbers of children with defined levels of hearing loss in their best hearing ear. Data should not be presented with ears as the unit of analysis since observations on the different ears of the same child cannot be regarded as independent. Assessors of outcomes should be blinded to the treatment allocation. Improvement should be clearly defined, for example authors should present data for children with bilateral OME resolving in one but not both ears. Analysis should be on the basis of intention-to-treat. A short course of oral steroids followed by longer-term topical intranasal steroids has so far not been evaluated.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-04-04 11:15:59 +0100" MODIFIED_BY="[Empty name]">
<P>Chantal L Thomas was a former lead author of the review and conducted the 2006 major update (<LINK REF="REF-Thomas-2006" TYPE="REFERENCE">Thomas 2006</LINK>), carrying out searching for trials, quality assessment of trials, data extraction and data analysis.</P>
<P>We wish to thank Dr Christine Clar, Dr Martin Burton and Ms Jenny Bellorini for editorial help, and Gemma Sandberg for conducting the update searches. In addition to peer reviewers, Dr Arne Ohlsson provided valuable feedback. We are grateful to Paul Harnett and Dr Richard Martin of the University of Bristol for identifying and bringing to our attention an error in our data entry for the study by Giebink and colleagues (<LINK REF="STD-Giebink-1990" TYPE="STUDY">Giebink 1990</LINK>) in a previous version of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-04-04 11:14:07 +0100" MODIFIED_BY="[Empty name]">
<P>Christopher C Butler: protocol development (with advice from C Clar), searching for trials, quality assessment of trials, data extraction and development of final review.</P>
<P>Judith van der Voort: searching for trials, quality assessment of trials, data extraction, data analysis and development of final review.</P>
<P>Ruth A Lewis: quality assessment of trials, data extraction, data analysis and development of updated review. Corresponding author.</P>
<P>Sharon A Simpson: quality assessment of trials, data extraction, data analysis and development of updated review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-03-28 13:46:38 +0100" MODIFIED_BY="[Empty name]">
<P>We adopted the Cochrane 'Risk of bias' method for assessing study quality (<LINK REF="REF-Handbook-2011" TYPE="REFERENCE">Handbook 2011</LINK>) at the 2010 update. We also added 'Summary of findings' tables; used the I² statistic to assess heterogeneity; and changed the analysis method for dichotomous outcomes from odds ratio (OR) to risk ratio (RR).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-03-28 14:05:30 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-03-28 13:59:51 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-03-28 13:59:27 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Berman-1990" MODIFIED="2011-03-28 13:58:48 +0100" MODIFIED_BY="[Empty name]" NAME="Berman 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-03-28 13:58:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berman S, Grose K, Nuss R, Huber-Navin C, Roark R, Gabbard SA, et al</AU>
<TI>Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>8</NO>
<PG>533-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giebink-1990" MODIFIED="2010-11-30 12:51:01 +0000" MODIFIED_BY="[Empty name]" NAME="Giebink 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-30 12:50:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Giebink GC, Batalden PB, Le CT, Russ JN, Knox JK, Anderson RS, et al</AU>
<TI>Randomized controlled trial comparing trimethoprim-sulfamethoxazole, prednisone, ibuprofen, and no treatment in chronic otitis media with effusion</TI>
<SO>Lim DJ, Bluestone CD, Klein JO, Nelson JD, editor(s). Recent Advances in Otitis Media: IVth International Symposium on Otitis Media with Effusion</SO>
<YR>1988</YR>
<PG>240-4</PG>
<PB>B.C. Decker Company</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-30 12:51:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Giebink GS, Batalden PB, Le CT, Lassman FM, Buran DJ, Seltz AE</AU>
<TI>A controlled trial comparing three treatments for chronic otitis media with effusion</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>1</NO>
<PG>33-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hemlin-1997" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Hemlin 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hemlin C, Carenfelt C, Papatziamos G</AU>
<TI>Single dose of betamethasone in combined medical treatment of secretory otitis media</TI>
<SO>Annals of Otology Rhinology and Laryngology</SO>
<YR>1997</YR>
<VL>106</VL>
<PG>359-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambert-1986" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Lambert 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lambert PR</AU>
<TI>Oral steroid therapy for chronic middle ear perfusion: a double-blind crossover study</TI>
<SO>Otolaryngology - Head and Neck Surgery</SO>
<YR>1986</YR>
<VL>95</VL>
<PG>193-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macknin-1985" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Macknin 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maknin ML, Jones PK</AU>
<TI>Oral dexamethasone for treatment of persistent middle ear effusion</TI>
<SO>Pediatrics</SO>
<YR>1985</YR>
<VL>75</VL>
<PG>329-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandel-2002" MODIFIED="2008-10-26 12:52:34 +0000" MODIFIED_BY="[Empty name]" NAME="Mandel 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandel EM, Casselbrant ML, Rockette HE, Fireman P, Kurs-Lasky M, Bluestone CD</AU>
<TI>Systemic steroid for chronic otitis media with effusion in children</TI>
<SO>Pediatrics</SO>
<YR>2002</YR>
<VL>110</VL>
<NO>6</NO>
<PG>1071-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niederman-1984" MODIFIED="2011-03-28 13:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Niederman 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-03-28 13:59:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Niederman LG, Walter-Bucholtz V, Jabalay T</AU>
<TI>A comparative trial of steroids versus placebos for treatment of chronic otitis media with effusion</TI>
<SO>Recent Advances in Otitis Media with Effusion</SO>
<YR>1984</YR>
<PG>273-5</PG>
<ED>Lim DJ, Bluestone CD, Klein JO, Nelson JD</ED>
<PB>B.C. Decker Inc</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Podoshin-1990" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Podoshin 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Podoshin L, Fradis M, Ben-David Y, Faraggi D</AU>
<TI>The efficacy of oral steroids in the treatment of persistent otitis media with effusion</TI>
<SO>Archives of Otolaryngology - Head and Neck Surgery</SO>
<YR>1990</YR>
<VL>116</VL>
<PG>1404-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-1980" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Schwartz 1980" YEAR="1980">
<REFERENCE MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz RH, Puglese J, Schwartz DM</AU>
<TI>Use of a short course of prednisone for treating middle ear effusion; a double-blind crossover study</TI>
<SO>Annals of Otology, Rhinology and Laryngology</SO>
<YR>1980</YR>
<VL>89</VL>
<NO>Suppl 68</NO>
<PG>296-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapiro-1982" MODIFIED="2011-03-28 13:59:27 +0100" MODIFIED_BY="[Empty name]" NAME="Shapiro 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-03-28 13:59:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro GG, Bierman CW, Furukuwa CT, Pierson WE, Berman R, Donaldson J, et al</AU>
<TI>Treatment of persistent Eustachian tube dysfunction with aerosolised nasal dexamethasone phosphate versus placebo</TI>
<SO>Annals of Allergy</SO>
<YR>1982</YR>
<VL>49</VL>
<PG>81-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tracy-1998" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Tracy 1998" YEAR="1997">
<REFERENCE MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tracy JM, Demain JG, Hoffman KM, Goetz DW</AU>
<TI>Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>1998</YR>
<VL>80</VL>
<PG>198-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williamson-2009" MODIFIED="2010-11-23 13:53:04 +0000" MODIFIED_BY="[Empty name]" NAME="Williamson 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-23 13:53:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williamson I, Benge S, Barton S, Petrou S, Letley L, Fasey N, et al</AU>
<TI>A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral otitis media with effusion (OME) in primary care</TI>
<SO>Health Technology Assessment</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>37</NO>
<PG>1-144</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-03-28 13:59:51 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Berman-1987" MODIFIED="2008-10-26 12:52:34 +0000" MODIFIED_BY="[Empty name]" NAME="Berman 1987" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berman S, Grose K, Zerbe GO</AU>
<TI>Medical management of chronic middle-ear effusion</TI>
<SO>American Journal of Disease in Children</SO>
<YR>1987</YR>
<VL>141</VL>
<PG>690-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cengel-2006" MODIFIED="2010-11-23 13:53:17 +0000" MODIFIED_BY="[Empty name]" NAME="Cengel 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-23 13:53:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cengel S, Akyol MU</AU>
<TI>The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2006</YR>
<VL>70</VL>
<PG>639-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choung-2008" MODIFIED="2010-11-23 13:54:20 +0000" MODIFIED_BY="[Empty name]" NAME="Choung 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-23 13:54:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choung Y-H, Shin YR, Choi SJ, Park K, Park HY, Lee JB, et al</AU>
<TI>Management for the children with otitis media with effusion in the tertiary hospital</TI>
<SO>Clinical and Experimental Otorhinolaryngology</SO>
<YR>2008</YR>
<VL>1</VL>
<NO>4</NO>
<PG>201-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daly-1991" MODIFIED="2008-10-26 12:52:34 +0000" MODIFIED_BY="[Empty name]" NAME="Daly 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daly K, Giebink GS, Batalden PB, Anderson RS, Le CT, Lundgren B</AU>
<TI>Resolution of otitis media with effusion with the use of a stepped treatment regimen of trimethoprim-sulfamethoxazole and prednisone</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>7</NO>
<PG>500-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heary-1990" MODIFIED="2010-11-30 12:48:34 +0000" MODIFIED_BY="[Empty name]" NAME="Heary 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-30 12:48:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heary C, Hokanson J, Ury H, Chang C, Coplan B, Hall M</AU>
<TI>Lack of efficacy of short-term prednisone, trimethoprim-sulfamethoxazole, alone or combined, in persistent otitis media with effusion: season of entry as a possible determinant of outcome</TI>
<SO>American Journal of Disease in Childhood</SO>
<YR>1990</YR>
<VL>144</VL>
<PG>420</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega-del-Alamo-2005" MODIFIED="2011-03-28 13:59:42 +0100" MODIFIED_BY="[Empty name]" NAME="Ortega del Alamo 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-03-28 13:59:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortega del Alamo P, Rivera Rodríguez T, Sanz Fernández R</AU>
<TI>The effect of AM3 in the resolution of otitis media with effusion (OME) in paediatric patients</TI>
<SO>Acta Otorrinolaringologica Espanola</SO>
<YR>2005</YR>
<VL>56</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Persico-1978" MODIFIED="2008-10-26 12:52:34 +0000" MODIFIED_BY="[Empty name]" NAME="Persico 1978" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Persico M, Podoshin L, Fradis M</AU>
<TI>Otitis media with effusion: a steroid and antibiotic therapeutic trial before surgery</TI>
<SO>Annals of Otology, Rhinology and Laryngology</SO>
<YR>1978</YR>
<VL>87</VL>
<PG>191-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenfeld-1995" MODIFIED="2011-03-28 13:59:51 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenfeld 1995" YEAR="">
<REFERENCE MODIFIED="2011-03-28 13:59:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenfeld RM</AU>
<TI>Nonsurgical management of surgical otitis media with effusion</TI>
<SO>Journal of Laryngology and Otology</SO>
<YR>1995</YR>
<VL>109</VL>
<PG>811-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-1981" MODIFIED="2010-11-30 12:15:03 +0000" MODIFIED_BY="[Empty name]" NAME="Schwartz 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-11-30 12:15:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz RH</AU>
<TI>Otitis media with effusion: results of treatment with a short course of oral prednisone or intranasal beclomethasone</TI>
<SO>Otolaryngology - Head and Neck Surgery</SO>
<YR>1981</YR>
<VL>89</VL>
<PG>386-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woodhead-1986" MODIFIED="2010-11-30 12:48:39 +0000" MODIFIED_BY="[Empty name]" NAME="Woodhead 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-30 12:48:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woodhead JC, Milavetz G, Dusdieker LB, Booth BM, Wilmoth RN</AU>
<TI>Prednisone treatment of otitis media with effusion</TI>
<SO>American Journal of Disease in Childhood</SO>
<YR>1986</YR>
<VL>140</VL>
<PG>318</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-11-30 12:48:39 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-03-28 14:05:30 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-03-28 14:05:30 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Baggett-1997" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Baggett 1997" TYPE="JOURNAL_ARTICLE">
<AU>Baggett HC, Prazma J, Rose AS, Lane AP, Pillsbury HC</AU>
<TI>The role of glucocorticoids in endotoxin- mediated otitis media with effusion</TI>
<SO>Archives of Otolaryngology - Head and Neck Surgery</SO>
<YR>1997</YR>
<VL>123</VL>
<PG>41-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bennett-2001" MODIFIED="2011-02-23 11:01:29 +0000" MODIFIED_BY="[Empty name]" NAME="Bennett 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bennett KE, Haggard MP, Silva PA, Stewart, IA</AU>
<TI>Behaviour and developmental effects of otitis media with effusion in the teens</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2001</YR>
<VL>85</VL>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berman-1994" NAME="Berman 1994" TYPE="JOURNAL_ARTICLE">
<AU>Berman S, Roark R, Luckey D</AU>
<TI>Theoretical cost effectiveness of management options for children with persisting middle ear effusion</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>93</VL>
<PG>353-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bluestone-1988" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Bluestone 1988" TYPE="BOOK">
<AU>Bluestone CD, Klein JO</AU>
<SO>Otitis media in infants and children</SO>
<YR>1988</YR>
<PB>W.B. Saunders Company</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Browning-2010" MODIFIED="2011-03-28 14:00:06 +0100" MODIFIED_BY="[Empty name]" NAME="Browning 2010" TYPE="COCHRANE_REVIEW">
<AU>Browning GG, Rovers MM, Williamson I, Lous J, Burton MJ</AU>
<TI>Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2011-03-28 14:00:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-28 14:00:06 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001801.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chantzi-2005" MODIFIED="2011-03-28 14:00:46 +0100" MODIFIED_BY="[Empty name]" NAME="Chantzi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Chantzi FM, Bairmis T, Papadopoulos NG, Kafetzis DA</AU>
<TI>Otitis media with effusion: an effort to understand and clarify the uncertainties</TI>
<SO>Expert Review of Anti-infective Therapy</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>1</NO>
<PG>117-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davies-1998" MODIFIED="2010-11-23 13:50:57 +0000" MODIFIED_BY="[Empty name]" NAME="Davies 1998" TYPE="JOURNAL_ARTICLE">
<AU>Davies HTO, Crombie IK, Tavakoli M</AU>
<TI>When can odds ratios mislead?</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<NO>7136</NO>
<PG>989-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2008" MODIFIED="2011-03-28 14:01:01 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2008" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Analysing data and undertaking meta-analyses</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dempster-1991" MODIFIED="2010-11-18 10:33:05 +0000" MODIFIED_BY="[Empty name]" NAME="Dempster 1991" TYPE="JOURNAL_ARTICLE">
<AU>Dempster JH, MacKenzie K</AU>
<TI>Tympanometry in the detection of hearing impairments associated with otitis media with effusion</TI>
<SO>Clinical Otolaryngology and Allied Sciences</SO>
<YR>1991</YR>
<VL>16</VL>
<PG>157-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dengerink-1984" MODIFIED="2011-02-23 10:25:32 +0000" MODIFIED_BY="[Empty name]" NAME="Dengerink 1984" TYPE="JOURNAL_ARTICLE">
<AU>Dengerink JE, Porter JB</AU>
<TI>Childrens attitudes towards peers wearing hearing aids</TI>
<SO>Language, Speech and Hearing Services in Schools</SO>
<YR>1984</YR>
<VL>205-9</VL>
<PG>15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ducharme-2003" MODIFIED="2011-02-23 10:21:14 +0000" MODIFIED_BY="[Empty name]" NAME="Ducharme 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ducharme FM, Chabot G, Polychronakos C, Glorieux F, Mazer B</AU>
<TI>Safety profile of frequent short courses of oral glucocorticoids in acute pediatric asthma: impact on bone metabolism, bone density, and adrenal function</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>111</VL>
<NO>2</NO>
<PG>376-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gates-1996" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Gates 1996" TYPE="JOURNAL_ARTICLE">
<AU>Gates GA</AU>
<TI>Cost effectiveness considerations in otitis media treatment</TI>
<SO>Otolaryngology - Head and Neck Surgery</SO>
<YR>1996</YR>
<VL>114</VL>
<PG>525-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gouma-2010" MODIFIED="2011-03-28 14:02:40 +0100" MODIFIED_BY="[Empty name]" NAME="Gouma 2010" TYPE="OTHER">
<AU>Gouma P, Mallis A, Daniilidis V, Gouveris H, Armenakis N, Naxakis S</AU>
<TI>Behavioural trends in young children with conductive hearing loss: a case-control study</TI>
<SO>European Archives of Oto-Rhino-Laryngology</SO>
<YR>2010</YR>
<VL>268</VL>
<NO>1</NO>
<PG>63-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffin-2006" MODIFIED="2011-03-28 14:02:59 +0100" MODIFIED_BY="[Empty name]" NAME="Griffin 2006" TYPE="COCHRANE_REVIEW">
<AU>Griffin G, Flynn CA, Bailey RE, Schultz JK</AU>
<TI>Antihistamines and/or decongestants for otitis media with effusion (OME) in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-03-28 14:02:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-28 14:02:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003423.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haddard-1998" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Haddard 1998" TYPE="JOURNAL_ARTICLE">
<AU>Haddad J, Egusa K, Takoudes TG</AU>
<TI>Effects of 21-aminosteroid U-74389G on acute otitis media in a guinea pig model</TI>
<SO>Otolaryngology - Head and Neck Surgery</SO>
<YR>1998</YR>
<VL>118</VL>
<PG>44-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haggard-1991" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Haggard 1991" TYPE="OTHER">
<AU>Haggard M, Hughes E</AU>
<TI>Screening children's hearing: a review of the literature and the implications for otitis media</TI>
<SO>London: HMSO</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Handbook-2011" MODIFIED="2011-03-28 13:28:43 +0100" MODIFIED_BY="[Empty name]" NAME="Handbook 2011" TYPE="OTHER">
<TI>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HES-2010" MODIFIED="2011-02-23 10:17:21 +0000" MODIFIED_BY="[Empty name]" NAME="HES 2010" TYPE="OTHER">
<TI>Hospital Episode Statistics (HES online)</TI>
<SO>http://www.hesonline.nhs.uk/ (accessed 23 February 2010)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kazanas-1994" MODIFIED="2011-03-28 14:03:28 +0100" MODIFIED_BY="[Empty name]" NAME="Kazanas 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kazanas SG, Maw R</AU>
<TI>Tympanometry, stapedius reflex and hearing impairment in children with otitis media with effusion</TI>
<SO>Acta Oto-Laryngologica</SO>
<YR>1994</YR>
<VL>114</VL>
<PG>410-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lanphear-1997" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Lanphear 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lanphear BP, Byrd RS, Auinger P, Hall CB</AU>
<TI>Increasing prevalence of recurrent otitis media among children in the United States</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>99</VL>
<PG>468(a)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lous-1995a" MODIFIED="2011-03-28 14:03:39 +0100" MODIFIED_BY="[Empty name]" NAME="Lous 1995a" TYPE="JOURNAL_ARTICLE">
<AU>Lous J</AU>
<TI>Otitis media and reading achievement: a review</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>1995</YR>
<VL>32</VL>
<PG>105-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lous-1995b" MODIFIED="2011-03-28 14:03:48 +0100" MODIFIED_BY="[Empty name]" NAME="Lous 1995b" TYPE="JOURNAL_ARTICLE">
<AU>Lous J</AU>
<TI>Secretory otitis media in schoolchildren: is screening for secretory otitis media advisable?</TI>
<SO>Danish Medical Bulletin</SO>
<YR>1995</YR>
<VL>42</VL>
<NO>1</NO>
<PG>71-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MRC-Multi_x002d_Centre-Otitis-Media-Study-Group-1999" MODIFIED="2010-11-18 11:47:51 +0000" MODIFIED_BY="[Empty name]" NAME="MRC Multi-Centre Otitis Media Study Group 1999" TYPE="JOURNAL_ARTICLE">
<AU>MRC Multi-Centre Otitis Media Study Group</AU>
<TI>Sensitivity, specificity and predictive value of tympanometry in predicting a hearing impairment in otitis media with effusion</TI>
<SO>Clinical Otolaryngology and Allied Sciences</SO>
<YR>1999</YR>
<VL>24</VL>
<NO>4</NO>
<PG>294-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MRC-Multi_x002d_Centre-Otitis-Media-Study-Group-2001" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="MRC Multi-Centre Otitis Media Study Group 2001" TYPE="JOURNAL_ARTICLE">
<AU>MRC Multi-Centre Otitis Media Study Group</AU>
<TI>Risk Factors for Persistence of Bilateral Otitis Media with Effusion</TI>
<SO>Clinical Otolaryngology</SO>
<YR>2001</YR>
<VL>26</VL>
<PG>147-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2008" MODIFIED="2010-11-17 17:00:49 +0000" MODIFIED_BY="[Empty name]" NAME="NICE 2008" TYPE="BOOK">
<AU>National Institute for Health and Clinical Excellence</AU>
<SO>NICE Guideline 60: Surgical management of otitis media with effusion in children</SO>
<YR>February 2008 (www.nice.org.uk/nicemedia/pdf/CG60NICEguideline.pdf)</YR>
<PB>National Institute for Health and Clinical Excellence</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIH-2007" MODIFIED="2011-03-28 14:05:30 +0100" MODIFIED_BY="[Empty name]" NAME="NIH 2007" TYPE="OTHER">
<AU>EPR 3</AU>
<TI>Expert panel report 3: Guidelines for the Diagnosis and Management of Asthma</TI>
<SO>NIH Publication No. 07-4051. Bethesda, MD: U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program,</SO>
<YR>2007 (available at http://www.nhlbi.nih.gov/guidelines/asthma/asthmafullrpt.pdf)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nuss-1990" MODIFIED="2010-11-23 13:48:56 +0000" MODIFIED_BY="[Empty name]" NAME="Nuss 1990" TYPE="JOURNAL_ARTICLE">
<AU>Nuss R, Berman S</AU>
<TI>Medical management of persistent middle ear effusion</TI>
<SO>American Journal of Asthma and Allergy for Pediatricians</SO>
<YR>1990</YR>
<VL>4</VL>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-03-28 13:34:01 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenfeld-1991" MODIFIED="2010-11-17 17:21:57 +0000" MODIFIED_BY="[Empty name]" NAME="Rosenfeld 1991" TYPE="JOURNAL_ARTICLE">
<AU>Rosenfeld RM, Mandel EM, Bluestone CD</AU>
<TI>Systemic steroids for otitis media with effusion in children</TI>
<SO>Archives of Otolaryngology - Head and Neck Surgery</SO>
<YR>1991</YR>
<VL>117</VL>
<PG>984-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenfeld-1992" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenfeld 1992" TYPE="JOURNAL_ARTICLE">
<AU>Rosenfeld RM</AU>
<TI>New concepts for steroid use in otitis media with effusion</TI>
<SO>Clinical Pediatrics</SO>
<YR>1992</YR>
<VL>31</VL>
<NO>10</NO>
<PG>615-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schappert-1992" MODIFIED="2008-10-26 12:52:34 +0000" MODIFIED_BY="[Empty name]" NAME="Schappert 1992" TYPE="BOOK">
<AU>Schappert SM</AU>
<TI>Office Visits for Otitis Media: United States, 1975-90</TI>
<SO>Advance data from vital and health statistics; no 214</SO>
<YR>1992</YR>
<PB>National Center for Health Statistics</PB>
<CY>Hyattsville, Maryland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stool-1994" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Stool 1994" TYPE="OTHER">
<AU>Stool SE, Berg AO, Berman S et al</AU>
<TI>Otitis media with effusion in young children. Clinical practice guideline. Number 12</TI>
<SO>Agency for Health Care Policy and Research, Public Health Services, US Department of Health and Human Services</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-1997" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Tan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tan G, Escoubet B, van den Abbeele G, Friedlander P, Huy TB, Herman P</AU>
<TI>Modulation of middle ear epithelial function by steroids: clinical relevance</TI>
<SO>Acta Otolaryngologica (Stockholm)</SO>
<YR>1997</YR>
<VL>117</VL>
<PG>284-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-1993" MODIFIED="2011-03-28 14:04:51 +0100" MODIFIED_BY="[Empty name]" NAME="Williams 1993" TYPE="JOURNAL_ARTICLE">
<AU>Williams RL, Chalmers TC, Stange KC, Chalmers FT, Bowlin SJ</AU>
<TI>Use of antibiotics in preventing recurrent acute otitis media and in treating otitis media with effusion</TI>
<SO>JAMA</SO>
<YR>1993</YR>
<VL>270</VL>
<PG>1344-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2008" MODIFIED="2011-02-23 10:22:45 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wu CT, Tsai SC, Lin JJ, Hsia SH</AU>
<TI>Disseminated varicella infection in a child receiving short-term steroids for asthma</TI>
<SO>Pediatric Dermatology</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>4</NO>
<PG>484-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yaman-2008" MODIFIED="2011-02-23 11:06:07 +0000" MODIFIED_BY="[Empty name]" NAME="Yaman 2008" TYPE="JOURNAL_ARTICLE">
<AU>Yaman H, Ozturk K, Uyar Y, Gurbilek M</AU>
<TI>Effectiveness of corticosteroids in otitis media with effusion: an experimental study</TI>
<SO>Journal of Laryngology and Otology</SO>
<YR>2008</YR>
<VL>122</VL>
<NO>1</NO>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-1985" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Yusuf 1985" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Peto R, Lewis J, Collins R, Sleight P</AU>
<TI>Beta blockade during and after myocardial infarction: an overview of the randomized trials</TI>
<SO>Progress in Cardiovascular Diseases</SO>
<YR>1985</YR>
<VL>27</VL>
<PG>335-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zielhuis-1990" MODIFIED="2011-03-28 13:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Zielhuis 1990" TYPE="JOURNAL_ARTICLE">
<AU>Zielhuis GA, Rach GH, van den Bosch AV, van den Broek PV</AU>
<TI>The prevalence of otitis media with effusion: a critical review of the literature</TI>
<SO>Clinical Otolaryngology</SO>
<YR>1990</YR>
<VL>15</VL>
<PG>283-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-03-28 14:05:14 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Butler-2001" MODIFIED="2010-11-30 12:37:54 +0000" MODIFIED_BY="[Empty name]" NAME="Butler 2001" TYPE="JOURNAL_ARTICLE">
<AU>Butler CC, van Der Voort JH</AU>
<TI>Steroids for otitis media with effusion: a systematic review</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>2001</YR>
<VL>155</VL>
<NO>6</NO>
<PG>641-7</PG>
<IDENTIFIERS MODIFIED="2010-11-30 12:37:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Butler-2002" MODIFIED="2011-03-28 14:05:05 +0100" MODIFIED_BY="[Empty name]" NAME="Butler 2002" TYPE="COCHRANE_REVIEW">
<AU>Butler CC, Van Der Voort JH</AU>
<TI>Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-03-28 14:05:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-28 14:05:05 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001935.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2006" MODIFIED="2011-03-28 14:05:14 +0100" MODIFIED_BY="[Empty name]" NAME="Thomas 2006" TYPE="COCHRANE_REVIEW">
<AU>Thomas CL, Simpson S, Butler CC, van der Voort JH</AU>
<TI>Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-03-28 14:05:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-28 14:05:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001935.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-03-28 14:15:02 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-03-28 14:15:02 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-03-28 13:46:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berman-1990">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial (patients who failed to respond at 2 weeks crossed over to alternative treatment)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-28 13:46:45 +0100" MODIFIED_BY="[Empty name]">
<P>68 children aged 6 months to 5.4 years recruited from the otitis clinic</P>
<P>Effusion present for at least 6 weeks and all had received at least 2 courses of antibiotics</P>
<P>Diagnosis (see '<LINK TAG="CRIT_PARTICIPANTS" TYPE="SECTION">Types of participants</LINK>'): 1B, 2B</P>
<P>77% bilateral effusions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-23 12:53:27 +0000" MODIFIED_BY="[Empty name]">
<P>Antibiotic (trimethoprim-sulfamethoxazole) for 30 days plus prednisone 0.5 to 1.0 mg/kg/dose/BD for first 7 days (n = 26) versus antibiotic plus placebo (n = 27)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 12:53:37 +0000" MODIFIED_BY="[Empty name]">
<P>Pneumo-otoscopy and tympanometry resolution and/or speech threshold no greater than a 15 dB hearing loss on audiometry</P>
<P>Follow up at 2 weeks (4-week data not used due to cross-over design)</P>
<P>Audiometry data used ear as unit of analysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 12:53:42 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-28 14:15:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giebink-1990">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, 4 parallel groups, open design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>76 children aged 10 months to 7.9 years. Participants identified by screening medical records of 16,609 consecutive children examined following a recent episode of OME.</P>
<P>Participants had continuous OME for at least 8 weeks, 3 or more episodes within previous 18 months and completed a course of antibiotic therapy for most recent acute OM</P>
<P>Diagnosis: 1B, 2C</P>
<P>60% bilateral</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-28 14:15:02 +0100" MODIFIED_BY="[Empty name]">
<P>Prednisone 1 mg/kg in tapering dose for 2 weeks (n = 18) versus no treatment controls (n = 19) (versus prednisone plus trimethoprim-sulfamethoxazole (n = 20) versus ibuprofen (n = 15))<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 12:55:35 +0000" MODIFIED_BY="[Empty name]">
<P>Pneumo-otoscopy and tympanometry resolution at 2 and 4 weeks after entry</P>
<P>There were no significant haematologic complications of medical treatment. Transient drop in serum cortisol in 14/17 treated with prednisone.</P>
<P>Patients who were considered treatment failure (at 4 weeks or beyond) were referred for surgical evaluation and discontinued the study. 78% were followed up for at least 4 months and 35% for 12 months.</P>
<P>Survival analyses performed on time from randomisation to clearance and time from clearance to relapse, but no data reported only Kaplan-Meier survival curves presented for illustrative purposes and therefore could not be included in our review</P>
<P>Comparative audiometry data used ear as unit of analysis and was based on only 29 (38%) patients who had an audiometric evaluation (39 patients remained in the study at 12 months); 24 had hearing loss</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 12:55:39 +0000" MODIFIED_BY="[Empty name]">
<P>Not placebo-controlled</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hemlin-1997">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial; 3 parallel groups with random allocation in ratio of 3:3:1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-23 12:57:23 +0000" MODIFIED_BY="[Empty name]">
<P>142 children aged from 2 to 12 years seen in the Department of Otolaryngology</P>
<P>Effusion present for at least 3 months</P>
<P>Diagnosis: 1B, 2C</P>
<P>84% bilateral</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-23 12:57:45 +0000" MODIFIED_BY="[Empty name]">
<P>Antibiotic for 10 days (cefixime) plus single dose of betamethasone 6 mg on day 10 (n = 59) versus antibiotic plus placebo (n = 61) (versus placebo only (n = 20))</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 12:58:07 +0000" MODIFIED_BY="[Empty name]">
<P>Otomicroscopy and tympanometry resolution</P>
<P>Cure defined as 1 of 2 affected ears clear or both clear after 1 ear affected 2 to 11 days after completion of treatment (treatment failures were not followed up beyond this)</P>
<P>Follow up also at 6 weeks and 6 months after completion of treatment, but for patients with OME resolution at preceding follow up only</P>
<P>Adverse effects classified as possibly or probably treatment-related included dermatitis, diarrhoea, loose stools, vomiting, stomach pain and gastroenteritis. 65% were mild and remainder moderate; none were serious. A further 8 participants experienced adverse effects that were deemed not related to treatment, group allocation not stated.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 12:58:13 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lambert-1986">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial (patients who failed to respond at 2 weeks crossed over to alternative treatment)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-23 12:59:04 +0000" MODIFIED_BY="[Empty name]">
<P>60 children aged from 2 to 15 years completed the study. Participants were recruited from the otolaryngology clinic.</P>
<P>Effusion present for at least 2 months</P>
<P>Diagnosis: 1A, 2C</P>
<P>72% bilateral</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-23 12:59:20 +0000" MODIFIED_BY="[Empty name]">
<P>Antibiotic (amoxycillin) plus prednisone 1.5 mg/kg daily in tapering doses (n = 32) versus antibiotic plus placebo (n = 28) for 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 12:59:25 +0000" MODIFIED_BY="[Empty name]">
<P>Resolution defined by otoscopy and tympanometry</P>
<P>Improvement defined by better hearing on pure tone audiometry</P>
<P>Not clear if resolution referred to clearing of both ears when bilateral OME at entry</P>
<P>Measured 7 to 10 days after completion of treatment</P>
<P>Audiometry data used ear as unit of analysis and present outcomes as ears resolving with each treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 12:59:26 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-28 13:48:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macknin-1985">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial; randomisation to strata based on history (recent acute versus non acute otitis) and age. Tympanometry 'blinded'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-23 13:00:21 +0000" MODIFIED_BY="[Empty name]">
<P>49 children aged from 6 months to 14 years. Participants were recruited from a hospital-based paediatric group practice.</P>
<P>Participants enrolled 6 weeks after initial presentation with acute OM (after completing antibiotic therapy for 10 days) or 3 weeks after initial presentation with non acute OME</P>
<P>Diagnosis: 1A, 2B</P>
<P>67% bilateral</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-23 13:00:30 +0000" MODIFIED_BY="[Empty name]">
<P>Dexamethasone 0.15 mg/kg in tapering doses for 2 weeks (n = 26) versus placebo (n = 23)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-28 13:48:04 +0100" MODIFIED_BY="[Empty name]">
<P>Audiometry, tympanometry and pneumo-otoscopy resolution</P>
<P>Improved hearing by at least 10 dB in 1 or both ears</P>
<P>Outcomes measured at 2 and 6 weeks after entering study</P>
<P>There were no statistically significant differences (Chi<SUP>2</SUP> or Fisher&#8217;s exact test) in the complications between the intervention groups rates as determined by daily phone reports and 19-symtpom checklist (actual data not reported). Severity of symptoms was not stated but none discontinued treatment due to adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 13:00:48 +0000" MODIFIED_BY="[Empty name]">
<P>Code broken early (and study terminated) because remission rates less than expected spontaneously</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mandel-2002">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial; 4 parallel groups, randomisation to strata based on age, laterality and duration of effusion</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-23 13:01:35 +0000" MODIFIED_BY="[Empty name]">
<P>144 children aged from 1 to 9 years seen in the OME research centre at a children's hospital</P>
<P>Effusion present for at least 2 months</P>
<P>Diagnosis: 1B, 2C</P>
<P>70% bilateral</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-23 13:01:49 +0000" MODIFIED_BY="[Empty name]">
<P>Prednisolone 0.5 mg/kg, twice a day for 10 days (max 30 mg), then once a day for 4 days (max 15 mg), plus antibiotic for either 28 days or 14 days (with placebo for 14 days) (n = 69) versus placebo plus antibiotic for either 28 days or 14 days (n = 66)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 13:02:31 +0000" MODIFIED_BY="[Empty name]">
<P>Audiometry, tympanometry and pneumatic otoscopy</P>
<P>Absence of OME and improved hearing</P>
<P>Data on hearing status, in terms of speech recognition threshold (SRT) and pure tone average (PTA), were reported separately for both right and left ear. Data on speech awareness threshold (SAT) were only reported for 26/144 (18%) participants (aged 12 to 29 months).</P>
<P>Possible side effects included vomiting, diarrhoea, increased appetite, hyperactivity and rash. Data presented separately for first 2 weeks of treatment (steroid treatment; included in the meta-analysis) and second 2 weeks of treatment (prolonged antibiotic treatment; 7/67 (10%) in steroid group and 9/65 (14%) in control). During week 1 to 2 steroid or placebo were discontinued due to adverse effects in 2 participants (placebo) and in week 3 to 4 amoxicillin or placebo was discontinued due to adverse effects in 3 participants (2 in steroid and 1 in placebo + antibiotic).</P>
<P>Allergy and immunological testing</P>
<P>Outcomes measured at 2 and 4 weeks after entry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 13:02:33 +0000" MODIFIED_BY="[Empty name]">
<P>Only 77% of the 188 participants required by sample size estimates were recruited</P>
<P>Participants with OME at 4 weeks after entry were discharged. Participants who had no middle ear effusion at 4 weeks were monitored for recurrence for up to 16 weeks after entry.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-28 13:48:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Niederman-1984">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-28 13:48:25 +0100" MODIFIED_BY="[Empty name]">
<P>26 children aged from 2 to 14 years seen in the hospital and medical centre-based Ambulatory Care Clinics</P>
<P>Effusion present for 8 weeks</P>
<P>Diagnosis: 1B, 2C</P>
<P>77% bilateral</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-23 13:04:02 +0000" MODIFIED_BY="[Empty name]">
<P>Dexamethasone 0.15 mg/kg tapering over 2 weeks (n = 12) versus placebo (n = 10)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 13:04:05 +0000" MODIFIED_BY="[Empty name]">
<P>Pneumo-otoscopy and tympanometry resolution in both ears</P>
<P>Outcomes measured at 2 and 5 weeks after study entry</P>
<P>No significant side effects observed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 13:04:07 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Podoshin-1990">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial; 3 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-23 13:05:13 +0000" MODIFIED_BY="[Empty name]">
<P>150 children aged between 3 and 8 years seen in the Department of Otolaryngology</P>
<P>Previously untreated OME, present for at least 2 months</P>
<P>Diagnosis: 1B, 2B; children also had audiometry at entry</P>
<P>Not stated how many bilateral</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-23 13:05:31 +0000" MODIFIED_BY="[Empty name]">
<P>Antibiotic (amoxycillin) plus prednisone 1 mg/kg daily in tapering doses (n = 50) for 2 weeks versus antibiotic plus placebo (n = 49) (vs placebo alone (n = 37))</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 13:05:39 +0000" MODIFIED_BY="[Empty name]">
<P>Audiometry and tympanometry improvement. Criteria for complete, partial or no improvement reported in terms of audiometric and tympanometric evaluations combined, but results reported separately for audiometry and tympanometry. Tympanometry data (complete) used for meta-analyses for OME resolution and audiometry data (complete) used to represent hearing loss (complete assumed to be based on closure of air-born gap and partial some conductive hearing loss).</P>
<P>Follow up at 2 months after entry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 13:05:41 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwartz-1980">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial (patients who failed to respond at 1 week crossed over to alternative treatment)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-23 13:06:28 +0000" MODIFIED_BY="[Empty name]">
<P>41 children aged 1.2 to 10 years seen by 2 paediatricians in separate private clinics</P>
<P>Effusions present for at least 3 weeks despite previous antibiotics and/or decongestants</P>
<P>Diagnosis: 1B, 2C</P>
<P>48% bilateral</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-23 13:06:38 +0000" MODIFIED_BY="[Empty name]">
<P>Antibiotic (sulfisoxazole) plus prednisone 1 mg/kg/day tapering over 7 days (n = 24) versus antibiotic plus placebo (n = 17)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 13:06:46 +0000" MODIFIED_BY="[Empty name]">
<P>Tympanometry and pneumo-otoscopy clearing of effusions</P>
<P>Follow up at 1 week after entry (data for the period after participants cross-over have not been included)</P>
<P>Not clear whether 'cleared' refers to clearing in all affected ears</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-20 15:54:38 +0100" MODIFIED_BY="[Empty name]">
<P>Not clear why numbers in treatment groups unbalanced. Small sample size therefore likely due to chance, but the number of participants enrolled and randomised not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-28 13:48:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shapiro-1982">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>45 children aged from 2 to 10 years. Study conducted at the Children's Orthopedic Hospital and Medical Centre.</P>
<P>All had persistent Eustachian tube dysfunction (documented with abnormal tympanometry) due to allergic rhinitis which failed to respond to 4 weeks of oral antihistamine and decongestants</P>
<P>Diagnosis: 1B, 2C</P>
<P>61% bilateral</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-23 13:08:01 +0000" MODIFIED_BY="[Empty name]">
<P>Aerosolised dexamethasone 1 spray in each nostril 3 times a day for 3 weeks (n = 21) versus aerosolised placebo (n = 24)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-28 13:48:51 +0100" MODIFIED_BY="[Empty name]">
<P>Improvement in middle ear pressure and gradient (data on ear pressure used in meta-analyses)</P>
<P>Physician assessment of mobility and position of tympanic membrane and presence of middle ear fluid</P>
<P>Follow up at 3 weeks after completing treatment</P>
<P>Transient drop in serum cortisol levels in 2 dexamethasone-treated patients; no adverse reactions, no pathological nasal mucosal changes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 13:08:19 +0000" MODIFIED_BY="[Empty name]">
<P>All children had allergic rhinitis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-28 13:49:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tracy-1998">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial; 3 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-28 13:49:08 +0100" MODIFIED_BY="[Empty name]">
<P>61 children aged from 3 to 11 years recruited from a military-dependent population referred to the Medical Centre-based paediatric Chronic Ear Clinic</P>
<P>Participants had persistent middle ear effusion for at least 3 months and a minimum of 3 episodes of acute OM within past 6 months or 4 in past year</P>
<P>Diagnosis: 1B, 2C</P>
<P>Not clear how many bilateral</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-23 13:09:40 +0000" MODIFIED_BY="[Empty name]">
<P>Antibiotic (amoxycillin) plus aqueous intra-nasal beclomethasone 2 sprays BD in each nostril both for 12 weeks (n = 19) versus antibiotic plus placebo (n = 20) (versus antibiotic alone (n = 20))</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-02 17:28:27 +0000" MODIFIED_BY="[Empty name]">
<P>Tympanic pressures scores, otoscopic examination scores, symptom scores and OME resolution. For patient symptoms both a mean total score (using a visual analogue scale, range 0 to 100) and a mean score for 4 ear-associated symptoms were reported, but only the former is included in our meta-analyses. OME resolution was reported separately according to middle ear pressure criteria and otoscopic examination score criteria (the former was used in the meta-analysis).</P>
<P>Antibiotic plus placebo and antibiotic alone groups pooled for the outcomes relating to resolution of OME</P>
<P>Follow up at 4, 8 and 12 weeks after entry</P>
<P>Other than transient nasal stinging and epistaxis no significant side effects (that required discontinuation of treatment) were reported (numbers not stated)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 13:10:20 +0000" MODIFIED_BY="[Empty name]">
<P>Validation of symptom score not described</P>
<P>No differences in outcome between atopic and non-atopic subjects</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Williamson-2009">
<CHAR_METHODS MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial; randomisation using blocks of 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-23 13:11:25 +0000" MODIFIED_BY="[Empty name]">
<P>217 children aged 4 to 11 years presenting to the GP with 1 or more episodes of otitis media or ear-related problems in previous 12 months. 72 (33%) received active monitoring for 3 months prior to randomisation.</P>
<P>Diagnosis: 1C (tympanometry type B/B or B/C2), 2C (pure-tone audiometry was not used as an inclusion criterion, because of poor validity in young children and hearing threshold not known to be an effect modifier)</P>
<P>100% bilateral</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-23 13:11:39 +0000" MODIFIED_BY="[Empty name]">
<P>Topical nasal steroid mometasone furoate (50 mcg) (n = 105) versus placebo (n = 112) used once daily for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 13:12:06 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: proportion of children cleared of OME assessed by tympanometry (to type C1 or A in one or more ears) at 1 month after entry</P>
<P>Secondary: OME clearance at 3 and 9 months after entry; disease-specific functional status (OM8-30 score), hearing difficulty, days with earache (within 3 months), adverse effects, health utilities, resources and costs</P>
<P>Adverse effects were relatively minor and included cough, dry throat, epistaxis and nasal stinging. At 1 month 43 (55%) participants experienced adverse effects in the intervention group and 35 (45%) in the control.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 13:12:11 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BD: twice a day<BR/>OM: otitis media<BR/>OME: otitis media with effusion</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-03-28 13:50:44 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-11-23 13:40:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berman-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 13:40:04 +0000" MODIFIED_BY="[Empty name]">
<P>ALLOCATION<BR/>Randomly assigned, double-blinded</P>
<P>PARTICIPANTS<BR/>Patients with middle ear effusion of 2 months or longer</P>
<P>INTERVENTIONS<BR/>Compared antibiotic plus steroid with placebo plus placebo<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 13:40:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cengel-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 13:40:12 +0000" MODIFIED_BY="[Empty name]">
<P>ALLOCATION<BR/>Quasi-randomised trial, with every second child enrolled into treatment or control group. Families that did not want to their child to be in the group that they were allocated were allowed to change groups.</P>
<P>ANALYSIS<BR/>OME resolution using ears as unit of analysis rather than children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 13:41:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choung-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 13:41:16 +0000" MODIFIED_BY="[Empty name]">
<P>ALLOCATION<BR/>Randomised trial</P>
<P>PARTICIPANTS<BR/>84 children with OME diagnosed at a tertiary hospital aged 5 months to 12 years</P>
<P>INTERVENTIONS<BR/>Included 5 comparison groups, but did not use placebo: antibiotics (n = 16) versus antibiotics plus steroid (prednisolone) (n = 18) versus antibiotics plus antihistamines (n = 15) versus antibiotics plus steroids plus antihistamines (n = 17) versus mucolytics (n = 17). Blind outcome assessment was not reported and allocation of treatment does not appear to have been concealed. Quote: "after obtaining consent from parents or guardians, we consecutively and randomly prescribed....". No further information was provided on method of randomisation and allocation concealment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 13:41:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daly-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 13:41:25 +0000" MODIFIED_BY="[Empty name]">
<P>ALLOCATION<BR/>Stratified, allocation scheme unclear</P>
<P>PARTICIPANTS<BR/>Children aged 6 months to 8 years with preceding acute otitis media or OME identified through screening hospital notes of children being examined for an ear recheck and meeting specific inclusion criteria</P>
<P>INTERVENTIONS<BR/>Compared antibiotic plus steroid with placebo plus placebo<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heary-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Paper in abstract form only - no full publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ortega-del-Alamo-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>ALLOCATION:<BR/>Quasi-randomised (children recruited in a consecutive sequence, alternating the treatment groups to which they were assigned)</P>
<P>PARTICIPANTS:<BR/>62 children aged 2 to 8 years with a diagnosis of OME</P>
<P>INTERVENTIONS<BR/>Compared antibiotics treatment with or without associated AM3; AM3 is the active principle for Inmunoferon®, an immunomodulatory drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 13:41:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Persico-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 13:41:40 +0000" MODIFIED_BY="[Empty name]">
<P>ALLOCATION<BR/>Patients not randomised, open study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 09:25:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenfeld-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 09:25:58 +0000" MODIFIED_BY="[Empty name]">
<P>ALLOCATION<BR/>Patients not randomised (allocation according to carer preference)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 13:42:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwartz-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 13:42:54 +0000" MODIFIED_BY="[Empty name]">
<P>ALLOCATION<BR/>Double-blinded, cross-over, randomly-assigned</P>
<P>PARTICIPANTS<BR/>Children aged 14 months to 10 years with persistent OME for 3 weeks or more, despite antimicrobial and/or decongestant therapy</P>
<P>INTERVENTIONS<BR/>Compared antibiotic plus steroid with non-placebo control<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Woodhead-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-28 11:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Paper in abstract form only - no full publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>OME: otitis media with effusion</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-11-30 12:48:39 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-10-26 12:52:34 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-03-28 13:49:50 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-11-23 13:12:13 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 12:53:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berman-1990">
<DESCRIPTION>
<P>Quote: "randomly assigned from a random numbers table provided by statistician"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 15:47:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giebink-1990">
<DESCRIPTION>
<P>Method of sequence generation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 12:58:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hemlin-1997">
<DESCRIPTION>
<P>Method of random sequence generation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 15:46:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-1986">
<DESCRIPTION>
<P>Method of sequence generation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:00:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macknin-1985">
<DESCRIPTION>
<P>Table of random numbers used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 16:23:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mandel-2002">
<DESCRIPTION>
<P>Method of sequence generation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:04:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niederman-1984">
<DESCRIPTION>
<P>Quote: "randomised using a list of preselected random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 17:15:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Podoshin-1990">
<DESCRIPTION>
<P>Method of sequence generation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:06:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwartz-1980">
<DESCRIPTION>
<P>Method of sequence generation not state</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:08:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-1982">
<DESCRIPTION>
<P>Method of sequence generation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:10:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tracy-1998">
<DESCRIPTION>
<P>Method of sequence generation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:12:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Williamson-2009">
<DESCRIPTION>
<P>Computer-generated random number sequence used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-03-28 13:49:00 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-28 13:46:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berman-1990">
<DESCRIPTION>
<P>Quote: "investigator treating patient was blinded to the randomisation scheme"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 12:55:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giebink-1990">
<DESCRIPTION>
<P>Quote: "all medications dispensed by pharmacist outside of the clinical area"</P>
<P>Comment: allocation considered blind as it appears to have been remote</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 12:58:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hemlin-1997">
<DESCRIPTION>
<P>Quote: "The drugs were dispensed double blind by a double-dummy technique"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-28 13:47:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-1986">
<DESCRIPTION>
<P>Although the study was (double-blind) placebo-controlled it is not clear if the person enrolling patients was blind to treatment allocation and control truly indistinguishable from intervention</P>
<P>Quote: "placebo, which consisted of a cherry-flavoured lactose syrup, was given in the same manner"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:00:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macknin-1985">
<DESCRIPTION>
<P>Placebo-controlled study with randomisation performed by pharmacist</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:02:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mandel-2002">
<DESCRIPTION>
<P>Quote: "Randomised in a double-blind manner"</P>
<P>Comment: it is not clear if the person enrolling patients were blind to treatment allocation, but placebos were reported to have been supplied by the same pharmaceutical company as interventions and likely to be identical</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-28 13:48:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niederman-1984">
<DESCRIPTION>
<P>Quote: "[Interventions] were identical". "All medications were dispensed by the hospital pharmacist in a double-blind design".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:05:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Podoshin-1990">
<DESCRIPTION>
<P>Placebo-controlled with capsules being prepared by pharmacy for each child entered and then given to clinician; enrolment appears to have been done at outpatients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:07:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwartz-1980">
<DESCRIPTION>
<P>Quote: "Pulverized prednisone tables or lactose powder packed in unmarked gelatin capsules and placed in identical coded vials by a registered pharmacist"; patients are assumed to have been enrolled in the clinic</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-28 13:49:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-1982">
<DESCRIPTION>
<P>Although the study was placebo-controlled it is not clear if the person enrolling patients was blind to treatment allocation. Treatment "randomly assigned", no further information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:10:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tracy-1998">
<DESCRIPTION>
<P>Quote: "Preparation and dispensing of drugs as well as randomization of patients to each arm of the study was accomplished independently by a clinical pharmacologist"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:12:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Williamson-2009">
<DESCRIPTION>
<P>Drug supplier conducted randomisation and labelled the drugs, which were numbered in auditable sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-03-28 13:47:24 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-23 12:54:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berman-1990">
<DESCRIPTION>
<P>Unclear if outcome assessors were blind, but study reported as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-28 13:47:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giebink-1990">
<DESCRIPTION>
<P>Quote: "blinded protocol was not used because the drug protocols were different; however, objective outcome determinations were used"</P>
<P>Quote: [Audiometric examinations were performed at the end of follow up (12 months)] "'examiners were unaware of the patient&#8217;s initial treatment assignment"</P>
<P>Nothing is reported for the 2 to 4-week assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-23 12:58:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hemlin-1997">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-23 12:59:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lambert-1986">
<DESCRIPTION>
<P>Unclear if outcome assessors were blind, but study reported as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-23 13:01:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macknin-1985">
<DESCRIPTION>
<P>Blind outcome assessors not reported but "double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-23 13:02:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandel-2002">
<DESCRIPTION>
<P>Unclear if outcome assessors were blind, but study reported as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-23 13:04:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niederman-1984">
<DESCRIPTION>
<P>Unclear if outcome assessors were blind, but study reported as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-23 13:05:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Podoshin-1990">
<DESCRIPTION>
<P>Unclear if outcome assessors were blind, but study reported as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-23 13:07:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwartz-1980">
<DESCRIPTION>
<P>Unclear if outcome assessors were blind, but study reported as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-23 13:08:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shapiro-1982">
<DESCRIPTION>
<P>Placebo-controlled study, although unclear if outcome assessors were blind</P>
<P>Quote: "At the conclusion of the study the code was broken"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-23 13:10:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tracy-1998">
<DESCRIPTION>
<P>Unclear if outcome assessors were blind, but study reported as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-21 14:20:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Williamson-2009">
<DESCRIPTION>
<P>Participants, research nurse and outcome assessors were blind. Success of blinding (children and parents) evaluated and maintained until analysis phase.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-03-28 13:49:50 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>&lt; 1 month</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>1 to 6 months</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 12:54:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berman-1990">
<DESCRIPTION>
<P>22% of patients who did not return for follow up were excluded from analysis (9 in prednisone group, 6 in placebo group; reasons not stated)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-23 12:54:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berman-1990">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 12:56:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giebink-1990">
<DESCRIPTION>
<P>4/76 (5%) participants excluded, group allocation not stated; 1 due to refusal to take steroid, 2 requiring additional treatment (1 for acute OM) and 1 met the exclusion criteria. Possible further 3 excluded from steroid group in analysis; inconsistencies in reporting. Outcome measures given as percentages, so actual numbers followed up not clear (although drop-outs would still be less than 10%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-23 12:56:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giebink-1990">
<DESCRIPTION>
<P>4/76 (5%) participants excluded, reasons as above. Possible further 3 excluded from steroid group in analysis; inconsistencies in reporting (although drop-outs would still be less than 10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 12:58:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hemlin-1997">
<DESCRIPTION>
<P>1 patient from cefixime plus placebo group (adverse event) and 1 from cefixime plus betamethasone group (withdrawal before starting treatment) excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-23 12:58:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hemlin-1997">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 12:59:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-1986">
<DESCRIPTION>
<P>60 participants included in analysis, but not clear if more were randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-23 12:59:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-1986">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 13:01:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macknin-1985">
<DESCRIPTION>
<P>Data presented for 49 participants, but 6 were taken off treatment during study (mainly due to acute OME) of which only 2 were included in analysis; study size therefore assumed to be 53 and loss to follow up 8%; 2 participants in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-23 13:01:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macknin-1985">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 13:03:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandel-2002">
<DESCRIPTION>
<P>Analyses were done on the basis of the intention-to-treat principle (analysed according to group allocation) but missing data excluded. Loss to follow up was fairly low (6%) and comparable between groups: intervention 4/73, control 5/71; reason not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-23 13:03:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandel-2002">
<DESCRIPTION>
<P>Analyses were done on the basis of the intention-to-treat principle (analysed according to group allocation) but missing data excluded. Loss to follow up was fairly low (8%) and comparable between groups: intervention 6/73, control 6/71; reason not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 13:04:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niederman-1984">
<DESCRIPTION>
<P>4/26 (15%) participants excluded from analyses, group allocation not stated; due to non-compliance with medication or follow-up visits</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-09-23 17:08:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niederman-1984">
<DESCRIPTION>
<P>Missing data for 30% (6/26), group allocation not stated; due to non-compliance with medication or follow-up visits</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 13:06:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Podoshin-1990">
<DESCRIPTION>
<P>Not analysed by intention-to-treat; 14 (9%) participants were excluded from the analyses, group allocation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-23 13:06:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Podoshin-1990">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 13:07:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwartz-1980">
<DESCRIPTION>
<P>41 participants included in study, but not clear if only 41 were randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-23 13:07:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwartz-1980">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 13:08:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shapiro-1982">
<DESCRIPTION>
<P>Loss to follow up 2%; 1 participant in placebo group excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-23 13:08:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-1982">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 13:10:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tracy-1998">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-23 13:10:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tracy-1998">
<DESCRIPTION>
<P>2 participants (3%) were lost to follow up due to families moving away (group allocation not stated) and excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 13:12:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williamson-2009">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-23 13:12:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williamson-2009">
<DESCRIPTION>
<P>Analysis of primary outcome based on intention-to-treat (analysed according to group allocation). Missing data assumed to be missing at random and not included in analyses. Loss to follow up was fairly high: 11% at 1 month (data not used in our meta-analysis), 21% at 3 months, 34% at 9 months. Missing data assumed to be missing at random and not included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-03-28 13:47:01 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-28 13:47:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berman-1990">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 12:56:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giebink-1990">
<DESCRIPTION>
<P>Poor reporting of results. Outcome measures given as percentages and unclear if number of participants in intervention group was 18 or 15, although this is unlikely to affect the findings of our review. Study follow up was up to 12 months, but useable data only presented for 2 and 4 weeks follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 12:58:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hemlin-1997">
<DESCRIPTION>
<P>Follow-up data were not reported for participants who did not have resolution 2 to 11 days after completing treatment. Longer-term follow up therefore only considers relapse rates for a subgroup of patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 12:59:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-1986">
<DESCRIPTION>
<P>Poor reporting of results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-23 16:22:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macknin-1985">
<DESCRIPTION>
<P>Study terminated early due to concern that steroid was impairing resolution. Likely to result in lack of power rather than bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:03:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandel-2002">
<DESCRIPTION>
<P>Follow-up data were not reported for participants who did not have resolution after completing treatment. Longer-term follow up therefore only considers relapse rates for a subgroup of patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:04:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niederman-1984">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 12:34:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Podoshin-1990">
<DESCRIPTION>
<P>Poor reporting of results. Confusion about outcomes; 'success' defined as normal otoscopy, tympanometry and closure of air-bone gap. No absolute values for audiometry data. Yet outcomes for 'complete improvement' are given according to audiometry and tympanometry separately (tympanometry data used in the review).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:07:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwartz-1980">
<DESCRIPTION>
<P>Poor reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:09:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-1982">
<DESCRIPTION>
<P>No values reported for physician-rated mobility and position of tympanic membrane and presence of middle ear fluid. No difference between groups reported but no P value given (or test reported).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-20 10:38:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tracy-1998">
<DESCRIPTION>
<P>OME resolution data reported as percentages. Mean tympanic membrane pressure and median otoscopic exam score were reported in graphical format only and data were presented separately for left and right ear; number of participants with unilateral and bilateral OME not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:12:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Williamson-2009">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-03-28 13:47:02 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-28 13:47:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berman-1990">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-19 10:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giebink-1990">
<DESCRIPTION>
<P>Some imbalance in baseline characteristics. Intervention group tended to be younger, had more bilateral OME, greater prior episodes and more likely to have had prior surgery than control group. However, the sample size was small and the inconsistency may be due to chance. Multivariate analysis indicated that none of these factors were significant covariates for any of the outcomes (results not reported).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 12:58:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hemlin-1997">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 12:59:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lambert-1986">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:01:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macknin-1985">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 15:18:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandel-2002">
<DESCRIPTION>
<P>More participants in steroid group were enrolled in winter but this is unlikely to have influenced the findings</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-20 15:47:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niederman-1984">
<DESCRIPTION>
<P>Some baseline imbalance, children slightly older, more bilateral and longer duration of OME in placebo group. Small sample size therefore could be due to chance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:06:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Podoshin-1990">
<DESCRIPTION>
<P>Few baseline characteristics reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:07:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwartz-1980">
<DESCRIPTION>
<P>Baseline characteristics not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:09:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-1982">
<DESCRIPTION>
<P>Groups reported to be similar for OME severity at baseline, no other characteristics reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:10:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tracy-1998">
<DESCRIPTION>
<P>More participants in the placebo group (45%) had a smoker present at home than in the intervention group (16%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 13:12:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Williamson-2009">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-03-28 13:58:30 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-03-28 13:53:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-03-28 13:50:51 +0100" MODIFIED_BY="[Empty name]">Summary of findings: oral steroids versus control</TITLE>
<TABLE COLS="7" ROWS="17">
<TR>
<TD COLSPAN="7">
<P>
<B>Oral steroids compared with inactive control for otitis media with effusion in children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: Children</B> <B>with</B> <B>otitis media with effusion</B>
</P>
<P>
<B>Settings: Hospital (secondary or tertiary care)</B>
</P>
<P>
<B>Intervention: Oral steroids for the treatment of OME</B>
</P>
<P>
<B>Comparison: Inactive control </B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Inactive control</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Oral steroids</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Hearing loss </B>
</P>
<P>[6 weeks]</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 1.09 (0.8 to 1.49)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>44<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
<P>+++O<BR/>moderate</P>
<P/>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Single RCT with small sample size</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>739 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>806 per 1000<BR/>(591 to 1101)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>OME resolution at short-term follow up (2 weeks) </B>
</P>
<P>[&lt; 1 month]</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 3.80 (0.93 to 15.52)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>108<BR/>(3)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>+++O<BR/>moderate<SUP>1</SUP>
</P>
<P/>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>50 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>190 per 1000<BR/>(47 to 776)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>OME resolution at intermediate-term follow up (4 to 6 weeks) </B>
</P>
<P>[1 to &lt; 6 months]</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 1.54 (0.76 to 3.14)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>106<BR/>(3)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>+++O<BR/>moderate<SUP>2</SUP>
</P>
<P/>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>111 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>169 per 1000<BR/>(84 to 345)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>OME resolution at long-term follow up </B>
</P>
<P>[&#8805; 6 months]</P>
<P/>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>No studies reported long-term outcome data</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Symptoms</B>
</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>No studies reported data on symptoms</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Adverse effects</B>
</P>
<P>[4 to 6 weeks]</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>143<BR/>(3)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>See comment<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>There were no serious adverse effects<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: confidence interval; OME: otitis media with effusion; RCT: randomised controlled trial; RR: risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Risk of bias in studies low, but overall sample size small and wide confidence interval.</P>
<P>
<SUP>2</SUP> Risk of bias fairly low, but overall sample size is small.</P>
<P>
<SUP>3</SUP> Two studies reported that there were no significant adverse effects, but did not give actual data (or description of adverse effects). One study only reported on haematological complications. The study also reported that there was a transient drop in serum cortisol levels in 14 steroid-treated patients.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2011-03-28 13:55:06 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-03-28 13:52:24 +0100" MODIFIED_BY="[Empty name]">Summary of findings: oral steroids plus antibiotic versus control plus antibiotic</TITLE>
<TABLE COLS="7" ROWS="18">
<TR>
<TD COLSPAN="7">
<P>
<B>Oral steroids plus antibiotics compared with inactive control plus antibiotics for otitis media with effusion in children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: Children</B> <B>with</B> <B>otitis media with effusion</B>
</P>
<P>
<B>Settings: Hospital (secondary or tertiary care)</B>
</P>
<P>
<B>Intervention: Oral steroids plus antibiotics for the treatment of OME</B>
</P>
<P>
<B>Comparison: Inactive control plus antibiotics</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Inactive control plus antibiotics</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Oral steroids plus antibiotics</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>
<B>Hearing loss </B>
</P>
<P>[2 months]<SUP>1</SUP>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>RR 1.01 (0.73 to 1.40)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>99<BR/>(1)<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>+++O<BR/>moderate<SUP>3</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>591 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>596 per 1000<BR/>(431 to 826)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>OME resolution at short-term follow up (7 to 28 days) </B>
</P>
<P>[&lt; 1 month]</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 1.99 (1.14 to 3.49)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>5<BR/>(409)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
<P/>
<P>++++<BR/>high</P>
<P/>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>500 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>999 per 1000<BR/>(570 to 1745)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>OME resolution at intermediate-term follow up (1 to 2 months) </B>
</P>
<P>[1 to &lt; 6 months]</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR1.44 (0.97 to 2.13)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>2<BR/>(231)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>++++<BR/>high</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>261 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>381 per 1000<BR/>(257 to 564)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>OME resolution at long-term follow up </B>
</P>
<P>[&#8805; 6 months]</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>No studies reported long-term outcome data</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Symptoms</B>
</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>No studies reported data on symptoms</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Adverse effects</B>
</P>
<P>[2 weeks to 6 months]</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 1.50 (0.81 to 2.78)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>255<BR/>(2)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
<P>++OO<BR/>low<SUP>4</SUP>
</P>
<P/>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>There were no serious adverse effects<SUP>5</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>178 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>267 per 1000<BR/>(144 to 495)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: confidence interval; OME: otitis media with effusion; RCT: randomised controlled trial; RR: risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Partial or no improvement on audiometry evaluation, definition of hearing loss not clear.</P>
<P>
<SUP>2 </SUP>Three studies that reported audiometry data used ears as the unit of allocation and were therefore not included in the analysis.</P>
<P>
<SUP>3</SUP> Single RCT.</P>
<P>
<SUP>4 </SUP>Severity of adverse effects not reported in one study, but the intervention was discontinued due to adverse effects in five participants (two in steroid group and three in control). For this study, treatments were administered in two phases (four-arm study analysed as two-arm) and adverse effects reported separately for both phases; data from end of first phase (completion of two-week steroid treatment) used in meta-analysis (during which no patient discontinued treatment due to adverse effects). Follow up in the second study was six months, but treatment failures were not followed up beyond two to 11 days.</P>
<P>
<SUP>5</SUP> Adverse effects were mainly mild to moderate and included dermatitis, diarrhoea, loose stools, vomiting, stomach pain and gastroenteritis.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2011-03-28 13:58:25 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-03-28 13:54:04 +0100" MODIFIED_BY="[Empty name]">Summary of findings: intranasal steroids versus control</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TD COLSPAN="7">
<P>
<B>Intranasal (topical) steroids compared with inactive control for otitis media with effusion in children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: Children</B> <B>with</B> <B>otitis media with effusion</B>
</P>
<P>
<B>Settings: Hospital or general practice (primary care)</B>
</P>
<P>
<B>Intervention: Intranasal steroids for the treatment of OME</B>
</P>
<P>
<B>Comparison: Inactive control</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Inactive control</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Intranasal steroids</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Median days with hearing loss </B>
</P>
<P>[3 months]</P>
</TD>
<TD ALIGN="CENTER">
<P>The median days with hearing loss for the control group was<BR/>4</P>
</TD>
<TD ALIGN="CENTER">
<P>The median days with hearing loss in the intervention groups was<BR/>the same at 4<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>200<BR/>[1]</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>+++O<BR/>moderate<SUP>1</SUP>
</P>
<P/>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>
<B>Hearing loss</B>
</P>
<P>
<B>(Audiometry failing)</B>
</P>
<P>[9 months]<SUP>2</SUP>
</P>
<P/>
</TD>
<TD COLSPAN="2">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>RR 1.17 (0.87 to 1.58)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>141<BR/>[1]</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>+++O<BR/>moderate<SUP>3</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>507 per 1000</P>
</TD>
<TD>
<P>593 per 1000<BR/>(441 to 801)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>OME resolution at short-term follow up (&lt; 1 month) </B>
</P>
<P>[3 weeks]</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 0.64 (0.31 to 1.31)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>44<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>+++O<BR/>moderate<SUP>4</SUP>
</P>
<P/>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>522 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>334 per 1000<BR/>(162 to 684)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>OME resolution at intermediate-term follow up (3 months) </B>
</P>
<P>[1 to &lt; 6 months ]</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 1.11 (0.85 to 1.46)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>172<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<BR/>+++O<BR/>moderate<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>523 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>577 per 1000<BR/>(442 to759)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>OME resolution at long-term follow up (9 months) </B>
</P>
<P>[&#8805; 6 months]</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 0.85 0.65 to 1.11)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>144<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>+++O<BR/>moderate<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>653 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>555 per 1000<BR/>(424 to 725)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Symptoms</B>
</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>No studies reported data on symptoms</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Adverse effects</B>
</P>
<P>[3 months]</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 1.26 (0.80 to 1.99)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>231<BR/>(2)<SUP>5</SUP>
</P>
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
<P>++OO<BR/>low<SUP>6</SUP>
</P>
<P/>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>There were no serious adverse effects in 2 studies (1 not included in analysis)<SUP>5</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>267 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>336 per 1000<BR/>(214 to 531)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: confidence interval; OME: otitis media with effusion; RCT: randomised controlled trial; RR: risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Single well-conducted RCT.</P>
<P>
<SUP>2</SUP> Fail on more than two frequencies in both ears at 0.5, 1, 2, 3, 4 kHz using hand-held audiometers at 25 dB HL.</P>
<P>
<SUP>3 </SUP>Single well-conducted RCT with 35%, 21% or 34% lost to follow up, respectively.</P>
<P>
<SUP>4</SUP> Single RCT with small sample size.</P>
<P>
<SUP>5</SUP> Adverse effects were relatively minor and included in analysis were cough, dry throat, epistaxis and nasal stinging. One study reported that there were no adverse reactions or pathological nasal mucosal changes (actual numbers not stated). The study also reported that there was a transient drop in serum cortisol levels in 2 steroid-treated patients.</P>
<P>
<SUP>6</SUP> Adverse effects poorly reported in one RCT and data only available for 40% of participants.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2011-03-28 13:58:30 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-03-28 13:55:44 +0100" MODIFIED_BY="[Empty name]">Summary of findings: intranasal steroids plus oral antibiotic versus control plus antibiotic</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Intranasal (topical) steroids plus oral antibiotics compared with inactive control plus oral antibiotics for otitis media with effusion in children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: Children</B> <B>with otitis media with effusion</B>
</P>
<P>
<B>Settings: Hospital (secondary or tertiary care)</B>
</P>
<P>
<B>Intervention: Intranasal steroids plus oral antibiotics for the treatment of OME</B>
</P>
<P>
<B>Comparison: Inactive control plus antibiotics</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Inactive control plus antibiotics</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Intranasal steroids plus oral antibiotics</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Hearing loss </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>No studies reported data on hearing loss</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>OME resolution at short-term follow up </B>
</P>
<P>[&lt; 1 month]</P>
<P/>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>No studies reported data on short-term follow up</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>OME resolution at intermediate-term follow up (3 months) </B>
</P>
<P>[1 to &lt; 6 months]</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>RR 1.26 (0.54 to 2.96)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>59<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>+++O<BR/>moderate<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>25 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>32 per 1000<BR/>(14 to 74)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>OME resolution at long-term follow up </B>
</P>
<P>[&#8805; 6 months]<B> </B>
</P>
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>No studies reported data on short-term follow up</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Symptom score</B>
</P>
<P>[3 months]</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean symptom score for the control group was<BR/>12.4 mm</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean symptom score in the intervention group was<BR/>4.5 mm lower<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>39<BR/>[1]</P>
</TD>
<TD ALIGN="CENTER">
<P>+++O<BR/>moderate<SUP>1</SUP>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Adverse effects</B>
</P>
<P>[3 months]</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>59<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>See comment<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>There were no significant side effects</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: confidence interval; OME: otitis media with effusion; RCT: randomised controlled trial; RR: risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Single RCT with small sample size.</P>
<P>
<SUP>2</SUP> One study reported that other than transient nasal stinging and epistaxis no significant side effects (that required discontinuation of treatment) were reported (actual numbers not stated).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-01-27 10:03:16 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-01-27 10:01:43 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Oral steroids versus control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-01-27 10:01:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Hearing loss at six weeks (hearing not improved by at least 10 dB in either ear)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.485137040430843" CI_START="0.8040502530479232" EFFECT_SIZE="1.092760180995475" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.17176652985318075" LOG_CI_START="-0.0947168070483404" LOG_EFFECT_SIZE="0.03852486140242021" MODIFIED="2010-09-02 17:41:59 +0100" MODIFIED_BY="[Empty name]" ORDER="32867" O_E="0.0" SE="0.1565336312097456" STUDY_ID="STD-Macknin-1985" TOTAL_1="26" TOTAL_2="23" VAR="0.02450277769970864" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7477833818465194" CI_END="15.522294915661377" CI_START="0.9322990929555485" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.804132157333604" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" I2="27.21405867677992" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.1909559305515223" LOG_CI_START="-0.03044473830902" LOG_EFFECT_SIZE="0.5802555961212511" METHOD="MH" MODIFIED="2011-01-27 10:01:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2531202110290457" P_Q="1.0" P_Z="0.06256708161976926" Q="0.0" RANDOM="YES" SCALE="119.6" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.42967483133608453" TOTALS="YES" TOTAL_1="56" TOTAL_2="52" WEIGHT="100.0" Z="1.8622555222381736">
<NAME>OME resolution (two weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.33460312224142" CI_START="1.498894840444533" EFFECT_SIZE="10.555555555555555" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8711910270406849" LOG_CI_START="0.1757711646583608" LOG_EFFECT_SIZE="1.0234810958495228" MODIFIED="2010-10-06 11:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="32861" O_E="0.0" SE="0.995898019627048" STUDY_ID="STD-Giebink-1990" TOTAL_1="18" TOTAL_2="19" VAR="0.9918128654970761" WEIGHT="36.21165765012137"/>
<DICH_DATA CI_END="7.255919064882729" CI_START="0.242660486745584" EFFECT_SIZE="1.3269230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8606924298030231" LOG_CI_START="-0.6150009355981109" LOG_EFFECT_SIZE="0.12284574710245615" MODIFIED="2010-10-06 10:47:13 +0100" MODIFIED_BY="[Empty name]" ORDER="32862" O_E="0.0" SE="0.8668295876365951" STUDY_ID="STD-Macknin-1985" TOTAL_1="26" TOTAL_2="23" VAR="0.7513935340022296" WEIGHT="43.58293502919893"/>
<DICH_DATA CI_END="102.6351940282196" CI_START="0.3418207620578995" EFFECT_SIZE="5.923076923076923" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0112963076703485" LOG_CI_START="-0.46620156193905815" LOG_EFFECT_SIZE="0.7725473728656451" MODIFIED="2010-10-06 10:53:19 +0100" MODIFIED_BY="[Empty name]" ORDER="32863" O_E="0.0" SE="1.455294512420808" STUDY_ID="STD-Niederman-1984" TOTAL_1="12" TOTAL_2="10" VAR="2.1178821178821177" WEIGHT="20.20540732067971"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6455359707052266" CI_END="3.1431645736730993" CI_START="0.7551678458377649" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5406546726032706" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.49736712093705626" LOG_CI_START="-0.12195651006660568" LOG_EFFECT_SIZE="0.1877053054352253" METHOD="MH" MODIFIED="2011-01-27 10:01:39 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.43921445953318994" P_Q="1.0" P_Z="0.2348112920473392" Q="0.0" RANDOM="YES" SCALE="32.73" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="51" WEIGHT="100.0" Z="1.1880561953172322">
<NAME>OME resolution (four to six weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.549023995086297" CI_START="0.706375738207283" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5501089356390392" LOG_CI_START="-0.15096422582863103" LOG_EFFECT_SIZE="0.1995723549052041" MODIFIED="2010-10-06 11:40:21 +0100" MODIFIED_BY="[Empty name]" ORDER="32864" O_E="0.0" SE="0.41181384541422816" STUDY_ID="STD-Giebink-1990" TOTAL_1="18" TOTAL_2="19" VAR="0.16959064327485382" WEIGHT="78.03844718502742"/>
<DICH_DATA CI_END="4.564099961619577" CI_START="0.04286411260044672" EFFECT_SIZE="0.4423076923076923" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6593551476445938" LOG_CI_START="-1.3679061628790066" LOG_EFFECT_SIZE="-0.3542755076172063" MODIFIED="2010-10-06 11:41:24 +0100" MODIFIED_BY="[Empty name]" ORDER="32865" O_E="0.0" SE="1.190823328906894" STUDY_ID="STD-Macknin-1985" TOTAL_1="26" TOTAL_2="23" VAR="1.4180602006688963" WEIGHT="9.33288336562635"/>
<DICH_DATA CI_END="24.33841901402626" CI_START="0.4400755774432298" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3862923637139084" LOG_CI_START="-0.3564727324957841" LOG_EFFECT_SIZE="0.5149098156090622" MODIFIED="2010-10-06 11:59:27 +0100" MODIFIED_BY="[Empty name]" ORDER="32866" O_E="0.0" SE="1.0237088443399314" STUDY_ID="STD-Niederman-1984" TOTAL_1="11" TOTAL_2="9" VAR="1.047979797979798" WEIGHT="12.628669449346226"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-01-27 10:02:17 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Oral steroids plus antibiotic versus control plus antibiotic</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-01-27 10:02:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Hearing loss at two months (at least some conductive hearing loss)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4023894733995281" CI_START="0.7328751934424157" EFFECT_SIZE="1.013793103448276" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.14686864320150014" LOG_CI_START="-0.13496997817509768" LOG_EFFECT_SIZE="0.005949332513201218" MODIFIED="2010-10-21 12:17:38 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.16555340132028962" STUDY_ID="STD-Podoshin-1990" TOTAL_1="50" TOTAL_2="49" VAR="0.02740792868871687" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.81447385371607" CI_END="3.485952233392956" CI_START="1.137338697790247" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.991157546174121" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="46" I2="68.78529664454355" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.5423214318514309" LOG_CI_START="0.05588981620654546" LOG_EFFECT_SIZE="0.29910562402898816" METHOD="MH" MODIFIED="2011-01-27 10:02:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.012218821720228368" P_Q="1.0" P_Z="0.015937038611307103" Q="0.0" RANDOM="YES" SCALE="39.78" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2581126502602079" TOTALS="YES" TOTAL_1="210" TOTAL_2="199" WEIGHT="100.0" Z="2.4103542278722725">
<NAME>OME resolution (seven to 28 days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.817615462955811" CI_START="1.399035444967649" EFFECT_SIZE="2.5961538461538463" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.6828321321128897" LOG_CI_START="0.14582871760752417" LOG_EFFECT_SIZE="0.414330424860207" MODIFIED="2010-10-06 12:01:27 +0100" MODIFIED_BY="[Empty name]" ORDER="32868" O_E="0.0" SE="0.31543846389022456" STUDY_ID="STD-Berman-1990" TOTAL_1="26" TOTAL_2="27" VAR="0.09950142450142449" WEIGHT="22.829909463328335"/>
<DICH_DATA CI_END="4.012593440042451" CI_START="1.250589251674573" EFFECT_SIZE="2.2401129943502824" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="12" LOG_CI_END="0.603425158814132" LOG_CI_START="0.09711469176950006" LOG_EFFECT_SIZE="0.350269925291816" MODIFIED="2010-10-06 12:01:48 +0100" MODIFIED_BY="[Empty name]" ORDER="32869" O_E="0.0" SE="0.2974092746192494" STUDY_ID="STD-Hemlin-1997" TOTAL_1="59" TOTAL_2="61" VAR="0.08845227662954809" WEIGHT="23.557770322837957"/>
<DICH_DATA CI_END="1.5014215920314162" CI_START="0.5099333885055649" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.17650265718953095" LOG_CI_START="-0.29248655114490446" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2010-10-06 12:20:38 +0100" MODIFIED_BY="[Empty name]" ORDER="32870" O_E="0.0" SE="0.27548658250966984" STUDY_ID="STD-Lambert-1986" TOTAL_1="32" TOTAL_2="28" VAR="0.07589285714285714" WEIGHT="24.443599787016797"/>
<DICH_DATA CI_END="3.771491819443461" CI_START="1.0605882742151247" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="11" LOG_CI_END="0.5765131700462842" LOG_CI_START="0.025546821281678265" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-10-06 12:02:59 +0100" MODIFIED_BY="[Empty name]" ORDER="32871" O_E="0.0" SE="0.32364036059174167" STUDY_ID="STD-Mandel-2002" TOTAL_1="69" TOTAL_2="66" VAR="0.10474308300395258" WEIGHT="22.500118369843577"/>
<DICH_DATA CI_END="72.94765465540308" CI_START="1.5475566079990262" EFFECT_SIZE="10.625" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" LOG_CI_END="1.86301133342494" LOG_CI_START="0.18964654401975803" LOG_EFFECT_SIZE="1.026328938722349" MODIFIED="2010-10-06 12:03:29 +0100" MODIFIED_BY="[Empty name]" ORDER="32872" O_E="0.0" SE="0.9829427605859027" STUDY_ID="STD-Schwartz-1980" TOTAL_1="24" TOTAL_2="17" VAR="0.9661764705882352" WEIGHT="6.668602056973332"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.24651783590569032" CI_END="2.125840783943272" CI_START="0.9696170116722053" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.435705884998029" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.32753073467260635" LOG_CI_START="-0.013399773529938964" LOG_EFFECT_SIZE="0.15706548057133374" METHOD="MH" MODIFIED="2011-01-27 10:02:14 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6195377508043143" P_Q="1.0" P_Z="0.07093443516746559" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="114" WEIGHT="100.0" Z="1.8058969656737303">
<NAME>OME resolution (one to two months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.818479565491973" CI_START="0.901284325339211" EFFECT_SIZE="1.5938166311300639" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" LOG_CI_END="0.4500148904507793" LOG_CI_START="-0.04513818188801143" LOG_EFFECT_SIZE="0.20243835428138396" MODIFIED="2010-10-06 13:41:56 +0100" MODIFIED_BY="[Empty name]" ORDER="32873" O_E="0.0" SE="0.29085536573904375" STUDY_ID="STD-Mandel-2002" TOTAL_1="67" TOTAL_2="65" VAR="0.0845968437791929" WEIGHT="47.408124590203116"/>
<DICH_DATA CI_END="2.2450376397036615" CI_START="0.7605118718647168" EFFECT_SIZE="1.3066666666666666" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.35122362666609813" LOG_CI_START="-0.11889400206450863" LOG_EFFECT_SIZE="0.1161648123007948" MODIFIED="2010-10-06 12:30:25 +0100" MODIFIED_BY="[Empty name]" ORDER="32874" O_E="0.0" SE="0.27614942223615196" STUDY_ID="STD-Podoshin-1990" TOTAL_1="50" TOTAL_2="49" VAR="0.07625850340136055" WEIGHT="52.59187540979689"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3590592456531351" CI_END="2.1374467631514844" CI_START="0.8415368138316569" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3411711817651348" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.32989530667156947" LOG_CI_START="-0.07492688064569142" LOG_EFFECT_SIZE="0.12748421301293902" METHOD="MH" MODIFIED="2011-01-26 16:58:59 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.549029406979366" P_Q="1.0" P_Z="0.2170388022694838" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="127" WEIGHT="100.0" Z="1.2344405713463187">
<NAME>Mild to moderate adverse effects at two weeks to six months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.441072068433915" CI_START="0.6685983879476374" EFFECT_SIZE="1.7231638418079096" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6474878208361872" LOG_CI_START="-0.17483467486622867" LOG_EFFECT_SIZE="0.23632657298497922" MODIFIED="2010-10-21 15:41:00 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.483036304537602" STUDY_ID="STD-Hemlin-1997" TOTAL_1="59" TOTAL_2="61" VAR="0.23332407150134296" WEIGHT="24.23506963840541"/>
<DICH_DATA CI_END="2.1145110472150503" CI_START="0.7246482538526735" EFFECT_SIZE="1.237851662404092" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.32520995845052564" LOG_CI_START="-0.13987274995343435" LOG_EFFECT_SIZE="0.09266860424854566" MODIFIED="2010-10-22 12:30:04 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.273191885113022" STUDY_ID="STD-Mandel-2002" TOTAL_1="69" TOTAL_2="66" VAR="0.07463380609160661" WEIGHT="75.7649303615946"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-01-27 10:03:16 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Intranasal steroids versus control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="44" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-01-27 10:03:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="74" TOTAL_2="67" WEIGHT="0.0" Z="0.0">
<NAME>Audiometry failing at nine months (audiometry sweep at 25 dB HL, fail on more than two out of five frequencies in both ears)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.58437532902554" CI_START="0.8665140593693482" EFFECT_SIZE="1.1717011128775834" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="34" LOG_CI_END="0.19985807120291266" LOG_CI_START="-0.06222438637534762" LOG_EFFECT_SIZE="0.06881684241378253" MODIFIED="2010-08-17 16:20:20 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.15394853291055816" STUDY_ID="STD-Williamson-2009" TOTAL_1="74" TOTAL_2="67" VAR="0.023700150785313207" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2011-01-27 10:03:16 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Median days with hearing loss (three months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.511920530592981" CI_START="-4.511920530592981" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.0" MODIFIED="2010-08-17 16:01:06 +0100" MODIFIED_BY="[Empty name]" ORDER="118" SD_1="18.5" SD_2="13.7" SE="2.3020425712831636" STUDY_ID="STD-Williamson-2009" TOTAL_1="100" TOTAL_2="100" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.313060248571358" CI_START="0.31086084038397155" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6388888888888888" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.11828465375267914" LOG_CI_START="-0.507433983252068" LOG_EFFECT_SIZE="-0.19457466474969443" METHOD="MH" MODIFIED="2011-01-27 10:03:16 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.22286383756491313" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="21" TOTAL_2="23" WEIGHT="0.0" Z="1.2189483025114467">
<NAME>OME resolution (three weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.313060248571358" CI_START="0.31086084038397155" EFFECT_SIZE="0.6388888888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.11828465375267914" LOG_CI_START="-0.507433983252068" LOG_EFFECT_SIZE="-0.19457466474969443" MODIFIED="2010-10-07 14:49:52 +0100" MODIFIED_BY="[Empty name]" ORDER="32876" O_E="0.0" SE="0.36755022473379517" STUDY_ID="STD-Shapiro-1982" TOTAL_1="21" TOTAL_2="23" VAR="0.13509316770186333" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="50" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-01-27 10:03:13 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="86" WEIGHT="0.0" Z="0.0">
<NAME>OME resolution (three months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.455404661048865" CI_START="0.8482643585495001" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="45" LOG_CI_END="0.16298376145018517" LOG_CI_START="-0.07146878032883489" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2010-10-06 14:33:55 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.13771858359979547" STUDY_ID="STD-Williamson-2009" TOTAL_1="86" TOTAL_2="86" VAR="0.01896640826873385" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="40" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-01-27 10:03:11 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="72" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>OME resolution (nine months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1110519387256657" CI_START="0.6519133958785669" EFFECT_SIZE="0.851063829787234" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="47" LOG_CI_END="0.04573436152836764" LOG_CI_START="-0.18581009474387777" LOG_EFFECT_SIZE="-0.07003786660775507" MODIFIED="2010-10-06 14:35:35 +0100" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.13601035977786058" STUDY_ID="STD-Williamson-2009" TOTAL_1="72" TOTAL_2="72" VAR="0.018498817966903072" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-25 11:48:45 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="86" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse effects at three months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9941550205903098" CI_START="0.7972259147741099" EFFECT_SIZE="1.2608695652173914" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" LOG_CI_END="0.2997589162474841" LOG_CI_START="-0.09841859248475757" LOG_EFFECT_SIZE="0.10067016188136323" MODIFIED="2010-10-21 14:27:27 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.23389143963977496" STUDY_ID="STD-Williamson-2009" TOTAL_1="86" TOTAL_2="86" VAR="0.05470520553676649" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-11-23 13:49:41 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Topical intranasal steroid plus oral antibiotic versus control plus antibiotic or antibiotic alone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-07 16:07:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>OME resolution (three months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9617231272948086" CI_START="0.5387295835763612" EFFECT_SIZE="1.263157894736842" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.4715444566469328" LOG_CI_START="-0.2686291751293788" LOG_EFFECT_SIZE="0.10145764075877704" MODIFIED="2010-10-06 15:29:30 +0100" MODIFIED_BY="[Empty name]" ORDER="32878" O_E="0.0" SE="0.4347816552239736" STUDY_ID="STD-Tracy-1998" TOTAL_1="19" TOTAL_2="40" VAR="0.18903508771929825" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2010-10-21 12:19:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.76" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Symptom score at three months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2765499022249198" CI_START="-10.27654990222492" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="12.4" MODIFIED="2008-10-26 12:52:34 +0000" MODIFIED_BY="[Empty name]" ORDER="32879" SD_1="6.1" SD_2="11.6" SE="2.947273494711948" STUDY_ID="STD-Tracy-1998" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-03-28 13:49:51 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-03-28 13:49:51 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-03-28 13:49:51 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-03-28 14:08:29 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-03-28 14:08:29 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-09-16 16:51:30 +0100" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-28 14:08:29 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="4">
<TR>
<TH>
<P>CENTRAL</P>
</TH>
<TH>
<P>PubMed</P>
</TH>
<TH>
<P>EMBASE (Ovid)</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 1 OTITIS MEDIA WITH EFFUSION single term (MeSH)<BR/># 2 glue ear<BR/># 3 otitis media NEAR effusion* or middle ear NEAR effusion*<BR/># 4 eustachian tube NEAR effusion* OR eustachian tube NEAR dysfunction*<BR/># 5 nonsuppurative otitis OR non suppurative otitis<BR/># 6 tympanitis OR serous otitis OR secretory otitis OR otitis serosa.TI,AB.<BR/># 7 mucoid NEAR otitis OR mucous NEAR otitis OR seromucoid NEAR otitis<BR/># 8 mucoid NEAR middle ear OR mucous NEAR middle ear OR seromucoid NEAR middle ear<BR/># 9 adhesive NEAR otitis OR exudative NEAR otitis<BR/># 10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9<BR/># 11 STEROIDS explode all trees (MeSH)<BR/># 12 HYDROXYCORTICOSTEROIDS explode all trees (MeSH)<BR/># 13 GLUCOCORTICOIDS explode all trees (MeSH)<BR/># 14 ANTI-INFLAMMATORY AGENTS STEROIDS explode all trees (MeSH)<BR/># 15 GLUCOCORTICOSTEROIDS SYNTHETIC explode all trees (MeSH)<BR/># 16 steroid* OR corticosteroid* or glucocorticoid*<BR/># 17 beclomethasone OR betamethasone<BR/># 18 budesonide<BR/># 19 cortisone<BR/># 20 dexamethasone<BR/># 21 flunisolide<BR/># 22 fluticasone<BR/># 23 fludrocortisone<BR/># 24 hydrocortisone OR cortisol<BR/># 25 methylprednisolone<BR/># 26 mometasone<BR/># 27 prednisolone<BR/># 28 prednisone<BR/># 29 triamcinolone<BR/># 30 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR<BR/>#21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29<BR/># 31 #10 AND #30</P>
</TD>
<TD VALIGN="TOP">
<P>#1 "OTITIS MEDIA WITH EFFUSION" [Mesh]<BR/>#2 "glue ear" [tiab] OR ("otitis media" [tiab] AND effusion* [tiab]) OR ("middle ear" [tiab] AND effusion* [tiab]) OR ("eustachian tube" [tiab] AND effusion [tiab]) OR ("Eustachian tube" [tiab] AND dysfunction* [tiab]) OR "nonsuppurative otitis" [tiab] OR "non suppurrative otitis" [tiab] OR tympanitis [tiab] OR "serous otitis" [tiab] OR "secretory otitis" [tiab] OR "otitis serosa" [tiab] OR (mucoid [tiab] AND otitis [tiab]) OR (mucous [tiab] AND otitis [tiab]) OR (seromucoid [tiab] AND otitis [tiab]) OR (mucoid [tiab] AND "middle ear" [tiab] OR (mucous [tiab] AND "middle ear" [tiab]) OR (seromucoid [tiab] AND middle [tiab])<BR/>#3 #1 OR #2<BR/>#4 "STEROIDS" [Mesh] OR "HYDROXYCORTICOSTEROIDS" [Mesh] OR "GLUCOCORTICOIDS" [Mesh] OR "ANTI-INFLAMMATORY AGENTS STEROIDS" [Mesh] OR "GLUCOCORTICOSTEROIDS SYNTHETIC" [Mesh]<BR/>#5 steroid* [tiab] OR corticosteroid* [tiab] OR glucocorticoid* [tiab] OR beclomethasone [tiab] OR betamethasone [tiab] OR budesonide [tiab] OR cortisone [tiab] OR dexamethasone [tiab] OR flunisolide [tiab] OR fluticasone [tiab] OR fludrocortisone [tiab] OR hydrocortisone [tiab] OR cortisol [tiab] OR methylprednisolone [tiab] OR mometasone [tiab] OR prednisolone [tiab] OR prednisone [tiab] OR triamcinolone [tiab]<BR/>#6 #4 OR #5<BR/>#7 #3 AND #6<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 mucoid otitis media/<BR/>2 ((glue adj ear) or ((otitis adj media) and effusion*) or ((middle adj ear) and effusion*) or ((eustachian adj tube) and effusion) or ((Eustachian adj tube) and dysfunction*) or (nonsuppurative adj otitis) or (non adj suppurrative adj otitis) or tympanitis or (serous adj otitis) or (secretory adj otitis) or (otitis adj serosa) or (mucoid and otitis) or (mucous and otitis) or (seromucoid and otitis) or ((mucoid and middle) adj ear) or ((mucous and middle) adj ear) or (seromucoid and middle)).tw.<BR/>3 secretory otitis media/ or serous otitis media/<BR/>4 1 or 3 or 2<BR/>5 exp CORTICOSTEROID/<BR/>6 (steroid* or corticosteroid* or glucocorticoid* or beclomethasone or betamethasone or budesonide or cortisone or dexamethasone or flunisolide or fluticasone or fludrocortisone or hydrocortisone or cortisol or methylprednisolone or mometasone or prednisolone or prednisone or triamcinolone).tw.<BR/>7 6 or 5<BR/>8 4 and 7</P>
</TD>
</TR>
<TR>
<TH>
<P>Web of Science</P>
</TH>
<TH>
<P>BIOSIS Previews/ CAB Abstracts (Ovid)</P>
</TH>
<TH>
<P>CINAHL</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#1 TS=((glue adj ear) or ((otitis adj media) and effusion*) or ((middle adj ear) and effusion*) or ((eustachian adj tube) and effusion) or ((Eustachian adj tube) and dysfunction*) or (nonsuppurative adj otitis) or (non adj suppurrative adj otitis) or tympanitis or (serous adj otitis) or (secretory adj otitis) or (otitis adj serosa) or (mucoid and otitis) or (mucous and otitis) or (seromucoid and otitis) or ((mucoid and middle) adj ear) or ((mucous and middle) adj ear) or (seromucoid and middle))<BR/>#2 TS=(steroid* or corticosteroid* or glucocorticoid* or beclomethasone or betamethasone or budesonide or cortisone or dexamethasone or flunisolide or fluticasone or fludrocortisone or hydrocortisone or cortisol or methylprednisolone or mometasone or prednisolone or prednisone or triamcinolone)<BR/>#3 #1 AND #2<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 ((glue adj ear) or ((otitis adj media) and effusion*) or ((middle adj ear) and effusion*) or ((eustachian adj tube) and effusion) or ((Eustachian adj tube) and dysfunction*) or (nonsuppurative adj otitis) or (non adj suppurrative adj otitis) or tympanitis or (serous adj otitis) or (secretory adj otitis) or (otitis adj serosa) or (mucoid and otitis) or (mucous and otitis) or (seromucoid and otitis) or ((mucoid and middle) adj ear) or ((mucous and middle) adj ear) or (seromucoid and middle)).tw.<BR/>2 (steroid* or corticosteroid* or glucocorticoid* or beclomethasone or betamethasone or budesonide or cortisone or dexamethasone or flunisolide or fluticasone or fludrocortisone or hydrocortisone or cortisol or methylprednisolone or mometasone or prednisolone or prednisone or triamcinolone).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>S1 (MH "Otitis Media with Effusion")<BR/>S2 TX glue AND ear<BR/>S3 TX ( middle OR otitis OR eustachian ) and TX ( effusion OR serous OR secretory OR nonsuppurative OR mucoid )<BR/>S4 S1 or S2 or S3<BR/>S5 TX steroid* or corticosteroid* or glucocorticoid* or beclomethasone or betamethasone or budesonide or cortisone or dexamethasone or flunisolide or fluticasone or fludrocortisone or hydrocortisone or cortisol or methylprednisolone or mometasone or prednisolone or prednisone or triamcinolone<BR/>S6 (MH "Steroids") OR (MH " GLUCOCORTICOIDS")<BR/>S7 S5 or S6<BR/>S8 S4 and S7<BR/>
<BR/>
</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>